Ophthalmic sunscreen compositions and methods of use
Topical ophthalmic sunscreen compositions with ensulizole and a second agent provide direct UV protection for the eyes, addressing the limitations of existing wearable devices by effectively reducing UV-related eye conditions and improving tear-film stability.
Patent Information
- Application Number
- PCT/US2026/026963
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Existing UV-protective approaches for the eyes, such as sunglasses and tinted contact lenses, provide inconsistent protection and rely heavily on user compliance, failing to offer direct ocular photoprotection against UV radiation.
Topical ophthalmic sunscreen compositions containing ensulizole and a second therapeutic agent, which can be applied directly to the eye to attenuate, absorb, scatter, or filter UV radiation, providing direct ocular photoprotection.
The compositions effectively reduce UV exposure, mitigating conditions like photokeratitis, conjunctival degeneration, and cataracts by enhancing ocular surface protection and improving tear-film stability.
Smart Images

Figure US2026026963_12112026_PF_FP_ABST
Abstract
Description
Attorney Docket No.56964-703601OPHTHALMIC SUNSCREEN COMPOSITIONS AND METHODS OF USE CROSS-REFERENCE
[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 801,314 filed on May 7, 2025. The contents of the above-referenced application are incorporated by reference in their entirety.BACKGROUND
[0002] Ultraviolet radiation is part of the electromagnetic spectrum that reaches the earth from the sun. It has wavelengths shorter than visible light, making it invisible to the naked eye. These wavelengths are classified as UVA, UVB, or UVC. UVA has the longest of the three at 320-400 nano-meters. UVA is further divided into two wave ranges, UVA I, which measures 340-400 nanometers (nm, or billionths of a meter), and UVA II which extends from 320-340 nano-meters. UVB ranges from 290 to 320 nm. With even shorter rays, most UVC are fortunately absorbed by the ozone layer and does not reach the earth. Both UVA and UVB penetrate the Earth's atmosphere and play a key role in conditions such as premature skin aging, eye damage, hair damage, and certain skin cancers. Photoconjunctivitis and Photokeratitis describe conditions where ultraviolet radiation inflames and / or damages the delicate structures of the ocular surface (the conjunctiva and the cornea, respectively). UV exposure to the eyes (either direct or indirect) can cause severe redness, dryness, irritation, tearing, photosensitivity, and pain. This pain can be so severe as to cause chemosis and sloughing of the corneal epithelium with resultant scarring and even permanent vision loss.
[0003] Long-term ophthalmic exposure to UV radiation has been associated with permanent thickening of the conjunctiva (called a pingueculum), vascular proliferation and tissue growth over the cornea (called a pterygium), conjunctival discoloration (melanosis), even cancer (e.g., conjunctival / uveal melanoma). Long-standing UV exposure to the eyes has also been associated with damage to the internal structures of the eyes, e.g., the natural lens and the retina. Certain forms of cataracts (e.g., nuclear sclerosis), as well as macular degeneration have been linked to the damage caused by oxidative damage from UV exposure. Accordingly, protecting the ocular structures form UV radiation may be beneficial in preventing such oxidative damage that leads to all of these quite common ophthalmic conditions. Until recently, the only proposed mechanism to protect the eyes from UV radiation has been the use of glasses with UV protection, sunglasses, and tinted contact lenses.
[0004] The present disclosure relates generally to ophthalmic compositions and methods of use thereof. More particularly, the present disclosure relates to ophthalmic ultraviolet-protectiveAttorney Docket No.56964-703601compositions configured to attenuate, absorb, scatter, filter, reflect, quench, reduce, or otherwise mitigate ultraviolet radiation exposure to ocular tissues.
[0005] Ultraviolet (“UV”) radiation exposure has been associated with acute and chronic ocular injury affecting both anterior and posterior ocular structures. Exposure to ultraviolet radiation may contribute to photokeratitis, photoconjunctivitis, ocular surface inflammation, epithelial injury, conjunctival degeneration, pinguecula formation, pterygium formation, conjunctival melanosis, cataract formation, retinal oxidative stress, retinal degeneration, macular degeneration, ocular irritation, ocular redness, tear-film instability, dry eye symptoms, oxidative cellular injury, mitochondrial dysfunction, epithelial degeneration, ocular photoaging, and combinations thereof.
[0006] In addition to ultraviolet radiation, visible light exposure, high-energy visible (HEV) light exposure, blue light exposure, infrared radiation exposure, oxidative light stress, environmental exposure, and combinations thereof may contribute to ocular discomfort, oxidative stress, ocular surface injury, tear-film instability, retinal injury, and cosmetic ocular changes.
[0007] Existing ultraviolet-protective approaches primarily rely on external wearable devices including sunglasses, tinted contact lenses, UV-blocking lenses, protective eyewear, and combinations thereof. Such approaches may provide inconsistent protection and depend substantially on user compliance, environmental conditions, cosmetic preferences, environmental lighting conditions, and combinations thereof.
[0008] Accordingly, there exists a need for topical ophthalmic ultraviolet-protective compositions capable of providing direct ocular photoprotection at the ocular surface.SUMMARY
[0009] This present disclosure addresses one or more unmet needs in protecting the eyeball from UV radiation. Provided herein are topical ophthalmic sunscreen compositions and methods of using the same for protecting the eyeball from UV radiation.
[0010] In an aspect, the present disclosure provides a formulation comprising about 0.25 wt% to about 15 wt% of ensulizole and a second therapeutic agent. In some embodiments, the second therapeutic agent is selected from glycerin, propylene glycol, Soothe® Dry Eye, Biotrue® Hydration Boost Lubricant Eye Drops, Biotrue® Hydration Boost Lubricant Eye Drops, Blink® Triple Care Lubricating Eye Drops, Blink GelTears® Lubricating Eye Drops, Soothe® XP Emollient Eye Drops, Advanced Eye Relief / Redness Instant Relief, Alaway® Antihistamine Eye Drops, Opcon-A® Allergy Relief Eye Drops, Acuvail®, Pred Forte®, Lastacaft®, Combigan®, Lumigan®, Alphagan®, Refresh® Digital, Refresh® Relieva® PF Xtra, RefreshMega 3®,Attorney Docket No.56964-703601Refresh Optive ®, Resistasis®, Vuity®, Acular®, Albalon®, Albalon A®, FML Liquifilm® eyedrops, Celluvisc®, and Ganafort®.
[0011] In another aspect, the present disclosure provides an ophthalmic composition comprising about 0.25 wt% to about 15 wt% of ensulizole and a second therapeutic agent. In some embodiments, the second therapeutic agent is selected from glycerin, propylene glycol, Soothe® Dry Eye, Biotrue® Hydration Boost Lubricant Eye Drops, Biotrue® Hydration Boost Lubricant Eye Drops, Blink® Triple Care Lubricating Eye Drops, Blink GelTears® Lubricating Eye Drops, Soothe® XP Emollient Eye Drops, Advanced Eye Relief / Redness Instant Relief, Alaway® Antihistamine Eye Drops, Opcon-A® Allergy Relief Eye Drops, Acuvail®, Pred Forte®, Lastacaft®, Combigan®, Lumigan®, Alphagan®, Refresh® Digital, Refresh® Relieva® PF Xtra, RefreshMega 3®, Refresh Optive ®, Resistasis®, Vuity®, Acular®, Albalon®, Albalon A®, FML Liquifilm® eyedrops, Celluvisc®, and Ganafort®.
[0012] In another aspect, described herein is an ophthalmic sunscreen composition comprising about 0.25 wt% to about 15 wt% of ensulizole; and a second therapeutic agent. In some embodiments, the second therapeutic agent is selected from glycerin, propylene glycol, Soothe® Dry Eye, Biotrue® Hydration Boost Lubricant Eye Drops, Biotrue® Hydration Boost Lubricant Eye Drops, Blink® Triple Care Lubricating Eye Drops, Blink GelTears® Lubricating Eye Drops, Soothe® XP Emollient Eye Drops, Advanced Eye Relief / Redness Instant Relief, Alaway® Antihistamine Eye Drops, Opcon-A® Allergy Relief Eye Drops, Acuvail®, Pred Forte®, Lastacaft®, Combigan®, Lumigan®, Alphagan®, Refresh® Digital, Refresh® Relieva® PF Xtra, RefreshMega 3®, Refresh Optive ®, Resistasis®, Vuity®, Acular®, Albalon®, Albalon A®, FML Liquifilm® eyedrops, Celluvisc®, and Ganafort®.
[0013] In another aspect, provided herein are methods of ocular UV protection, the method comprising applying an ophthalmic composition to an eye, wherein the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and a second therapeutic agent. In some embodiments, the second therapeutic agent is selected from glycerin, propylene glycol, Soothe® Dry Eye, Biotrue® Hydration Boost Lubricant Eye Drops, Biotrue® Hydration Boost Lubricant Eye Drops, Blink® Triple Care Lubricating Eye Drops, Blink GelTears® Lubricating Eye Drops, Soothe® XP Emollient Eye Drops, Advanced Eye Relief / Redness Instant Relief, Alaway® Antihistamine Eye Drops, Opcon-A® Allergy Relief Eye Drops, Acuvail®, Pred Forte®, Lastacaft®, Combigan®, Lumigan®, Alphagan®, Refresh® Digital, Refresh® Relieva® PF Xtra, RefreshMega 3®, Refresh Optive ®, Resistasis®, Vuity®, Acular®, Albalon®, Albalon A®, FML Liquifilm® eyedrops, Celluvisc®, and Ganafort®.Attorney Docket No.56964-703601
[0014] Other features and advantages of the present invention will become apparent from the following more detailed description, when taken in conjunction with the accompanying drawings, which illustrate, by way of example, the principles of the invention.INCORPORATION BY REFERENCE
[0015] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and / or take precedence over any such contradictory material.BRIEF DESCRIPTION OF THE DRAWINGS
[0016] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also “Figure” and “FIG.” herein), of which:
[0017] FIG. 1 illustrates a schematic of ophthalmic ultraviolet protection provided by ensulizole-containing eye drops.
[0018] FIG 2A illustrates a line graph demonstrating the UV absorbance spectrum of eyedrops formulated with 0.25 wt% ensulizole versus commercially available Refresh Optive® Advanced Lubricant Eye Drops. Y-axis: Absorbance (A). X-axis: Wavelength (nm).
[0019] FIG 2B illustrates a line graph demonstrating the UV absorbance spectrum of eyedrops formulated with 0.25 wt% ensulizole versus commercially available Drop Defence® Anti UV Eyedrops. Y-axis: Absorbance (A). X-axis: Wavelength (nm).
[0020] FIG 2C illustrates a line graph demonstrating the UV absorbance spectrum of eyedrops formulated with 0.25 wt% ensulizole versus commercially available Rohto® Dual Light Relief Eyedrops. Y-axis: Absorbance (A). X-axis: Wavelength (nm).
[0021] FIG. 3 illustrates a flow chart of the procedure for measuring UV absorbance from eyedrop formulations described herein. A sample is processed via photospectrometry means, and absorbance is generated via computer readout.
[0022] FIG. 4A illustrates a line graph demonstrating the UVB absorbance spectrum of eyedrops formulated with 0.25 wt% ensulizole versus commercially available Refresh Optive® Advanced Lubricant Eye Drops. Y-axis: Absorbance (A). X-axis: Wavelength (nm).Attorney Docket No.56964-703601
[0023] FIG. 4B illustrates a line graph demonstrating the UVB absorbance spectrum of eyedrops formulated with 0.25 wt% ensulizole versus commercially available Drop Defence® Anti UV Eyedrops. Y-axis: Absorbance (A). X-axis: Wavelength (nm).
[0024] FIG. 4C illustrates a line graph demonstrating the UVB absorbance spectrum of eyedrops formulated with 0.25 wt% ensulizole versus commercially available Rohto® Dual Light Relief Eyedrops. Y-axis: Absorbance (A). X-axis: Wavelength (nm).DETAILED DESCRIPTION
[0025] The following description and examples illustrate embodiments of the present disclosure in detail. It is to be understood that this present disclosure is not limited to the particular embodiments described herein and as such can vary. Those of skill in the art will recognize that there are numerous variations and modifications of this present disclosure, which are encompassed within its scope.
[0026] Although various features of the present disclosure may be described in the context of a single embodiment, the features may also be provided separately or in any suitable combination. Conversely, although the present disclosure may be described herein in the context of separate embodiments for clarity, the present disclosure may also be implemented in a single embodiment.
[0027] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0028] All terms are intended to be understood as they would be understood by a person skilled in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosure pertains.
[0029] The following definitions supplement those in the art and are directed to the current application and are not to be imputed to any related or unrelated case, e.g., to any commonly owned patent or application. Although any methods and materials similar or equivalent to those described herein can be used in the practice for testing of the present disclosure, the preferred materials and methods are described herein. Accordingly, the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.
[0030] DEFINITIONS
[0031] As used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example reference to “the therapeutic agent” includes reference to one or more therapeutic agents (or to a plurality of therapeutic agents) and equivalents thereof known to those skilled in the art, and so forth.Attorney Docket No.56964-703601When ranges are used herein for physical properties, such as molecular weight, or chemical properties, such as chemical formulae, all combinations and subcombinations of ranges and specific embodiments therein are intended to be included.
[0032] The term “about” or “approximately” can mean within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, up to 15%, up to 10%, up to 5%, or up to 1% of a given value.
[0033] Whenever the term “at least,” “greater than,” or “greater than or equal to” precedes the first numerical value in a series of two or more numerical values, the term “at least,” “greater than” or “greater than or equal to” applies to each of the numerical values in that series of numerical values. For example, greater than or equal to 1, 2, or 3 is equivalent to greater than or equal to 1, greater than or equal to 2, or greater than or equal to 3.
[0034] Whenever the term “no more than,” “less than,” or “less than or equal to” precedes the first numerical value in a series of two or more numerical values, the term “no more than,” “less than,” or “less than or equal to” applies to each of the numerical values in that series of numerical values. For example, less than or equal to 3, 2, or 1 is equivalent to less than or equal to 3, less than or equal to 2, or less than or equal to 1.
[0035] The term “exemplary” as used herein means “serving as an example, instance, or illustration.” Any embodiment described herein as “exemplary” is not to be construed as preferred or advantageous over other embodiments.
[0036] The terms “determining,” “measuring,” “evaluating,” “assessing,” “assaying,” and “analyzing” are often used interchangeably herein to refer to forms of measurement. The terms include determining if an element is present or not (for example, detection). These terms can include quantitative, qualitative or quantitative and qualitative determinations. Assessing can be relative or absolute. “Detecting the presence of’ can include determining the amount of something present in addition to determining whether it is present or absent depending on the context.
[0037] The terms “subject,” “individual,” or “patient” are often used interchangeably herein. A “subject” can be a biological entity containing expressed genetic materials. The biological entity can be a plant, animal, or microorganism, including, for example, bacteria, viruses, fungi, and protozoa. The subject can be tissues, cells and their progeny of a biological entity obtained in vivo or cultured in vitro. The subject can be a mammal. The mammal can be human. The subjectAttorney Docket No.56964-703601may be diagnosed or suspected of being at high risk for a disease. In some cases, the subject is not necessarily diagnosed with or suspected of being at high risk for the disease.
[0038] As used herein, the term “about” a number refers to that number plus or minus 10% of that number. The term “about” a range refers to that range minus 10% of its lowest value and plus 10% of its greatest value.
[0039] As used herein, the terms “treatment” or “treating” are used in reference to a pharmaceutical or other intervention regimen for obtaining beneficial or desired results in the recipient. Beneficial or desired results include but are not limited to a therapeutic benefit and / or a prophylactic benefit. A therapeutic benefit may refer to eradication or amelioration of symptoms or of an underlying disorder being treated. Also, a therapeutic benefit can be achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the subject, notwithstanding that the subject may still be afflicted with the underlying disorder. A prophylactic effect includes delaying, preventing, or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof. For prophylactic benefit, a subject at risk of developing a particular disease, or to a subject reporting one or more of the physiological symptoms of a disease may undergo treatment, even though a diagnosis of this disease may not have been made.
[0040] While various embodiments of the invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions may occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed.
[0041] COMPOSITIONS
[0042] Ultraviolet (UV) radiation causes premature skin aging, damage to hair and eyes, and certain skin cancers. The eyes are particularly vulnerable; UV exposure can lead to conditions ranging from mild inflammation — such as photoconjunctivitis and photokeratitis — to more serious problems like conjunctival thickening (pingueculum), corneal growths (pterygium), discoloration (melanosis), cancers, and even blindness. UV radiation damages both the eye’s surface and internal structures, contributing to cataracts and macular degeneration through oxidative stress. Although sunglasses and similar wearable accessories provide some UV protection, they can be expensive and ineffective if not worn consistently. Therefore, there is a need for ocular UV protection that does not rely on wearable accessories.
[0043] Provided herein are compositions for ocular UV protection.Attorney Docket No. 56964-703601
[0044] In an aspect, described herein is a formulation comprising about 0.25 wt% to about 15 wt% of ensulizole. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and a second therapeutic agent.
[0045] In another aspect, described herein is an ophthalmic composition comprising about 0.25 wt% to about 15 wt% of ensulizole. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and a second therapeutic agent.
[0046] In yet another aspect, described herein is an ophthalmic sunscreen composition comprising about 0.25 wt% to about 15 wt% of ensulizole. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and a second therapeutic agent.
[0047] In certain embodiments, the compositions, formulations, ophthalmic compositions, or ophthalmic screen compositions further comprise one or more ophthalmically acceptable agents selected from lubricating agents, demulcents, osmoprotective agents, viscosity-enhancing agents, antioxidants, flavonoids, polyphenols, anti-inflammatory agents, antihistamines, vasoconstrictors, ocular decongestants, redness-reducing agents, cosmetic agents, artificial tear components, ophthalmic therapeutic agents, osmolarity-modifying agents, emulsifying agents, surfactants, buffering agents, preservatives, preservative-free vehicles, eye-whitening agents, or any combination thereof.
[0048] In certain embodiments, suitable redness-reducing agents include brimonidine tartrate, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, tetryzoline hydrochloride, naphazoline hydrochloride, phenylephrine hydrochloride, antazoline phosphate, pheniramine maleate, or any combination thereof.
[0049] In certain embodiments, suitable lubricating agents, demulcents, or artificial tear components include hyaluronic acid, sodium hyaluronate, crosslinked hyaluronic acid, hyaluronic acid derivatives, carboxymethylcellulose, carmellose sodium, glycerin, propylene glycol, polyethylene glycol, polypropylene glycol, povidone, polyvinyl alcohol, hydroxypropyl methylcellulose, hydroxyethyl cellulose, dextran 70, trehalose, erythritol, chondroitin sulfate, polysorbate 80, castor oil, mineral oil, light mineral oil, phospholipids, liposomal components, or any combination thereof.
[0050] In certain embodiments, the compositions, formulations, ophthalmic compositions, or ophthalmic screen compositions comprise hyaluronic acid, sodium hyaluronate, crosslinked hyaluronic acid, hyaluronic acid derivatives, or any combination thereof at concentrations of approximately 0.01 wt% to approximately 1 wt%.
[0051] In certain embodiments, hyaluronic acid, sodium hyaluronate, crosslinked hyaluronic acid, hyaluronic acid derivatives, glycerin, or combinations thereof improve ocular surfaceAttorney Docket No.56964-703601retention, prolong ocular residence time, improve tear-film stability, improve ocular lubrication, improve ocular hydration, reduce evaporation, improve environmental tolerability, reduce ultraviolet-induced tear-film instability, or any combination thereof.
[0052] In certain embodiments, the compositions, formulations, ophthalmic compositions, or ophthalmic screen compositions comprise approximately 1 wt% glycerin.
[0053] In certain embodiments, hyaluronic acid or sodium hyaluronate in combination with glycerin prolongs ocular surface residence time of the compositions, formulations, ophthalmic compositions, or ophthalmic screen compositions, described herein.
[0054] In certain embodiments, prolonged ocular residence time improves ultraviolet photoprotection, ocular comfort, tear-film persistence, ocular surface coverage, environmental stability, or any combination thereof.
[0055] In certain embodiments, the combination of ensulizole, hyaluronic acid, sodium hyaluronate, glycerin, or any combination thereof provides multifunctional ocular photoprotection with prolonged ocular surface retention and improved ophthalmic tolerability.
[0056] In certain embodiments, the compositions, formulations, ophthalmic compositions, or ophthalmic screen compositions comprise one or more flavonoids, polyphenols, polyphenolic compounds, plant-derived antioxidants, botanical antioxidants, or any combination thereof.
[0057] In certain embodiments, suitable flavonoids or polyphenolic compounds include quercetin, rutin, catechin, epicatechin, epigallocatechin gallate (EGCG), hesperidin, hesperetin, naringenin, luteolin, apigenin, kaempferol, myricetin, fisetin, genistein, daidzein, baicalein, baicalin, curcumin, resveratrol, proanthocyanidins, anthocyanins, tannic acid, ferulic acid, caffeic acid, gallic acid, chlorogenic acid, ellagic acid, rosmarinic acid, hydroxytyrosol, oleuropein, or combinations thereof.
[0058] In certain embodiments, the flavonoid or polyphenolic compound functions as an antioxidant, ultraviolet-scavenging agent, free-radical scavenger, reactive oxygen species (ROS)-reducing agent, anti-inflammatory agent, mitochondrial protective agent, epithelial protective agent, tear-film stabilizer, photoprotective agent, or any combination thereof.
[0059] In certain embodiments, the flavonoid or polyphenolic compound functions as an antioxidant, ultraviolet-scavenging agent, free-radical scavenger, reactive oxygen species (ROS)-reducing agent, anti-inflammatory agent, mitochondrial protective agent, epithelial protective agent, tear-film stabilizer, photoprotective agent, or any combination thereof.
[0060] In certain embodiments, the compositions, formulations, ophthalmic compositions, or ophthalmic screen compositions comprise quercetin or a pharmaceutically acceptable salt, ester, glycoside, hydrate, solvate, analog, derivative, nanoparticle formulation, liposomal formulation,Attorney Docket No.56964-703601sustained-release formulation, depot formulation, biodegradable polymer formulation, or any combination thereof.
[0061] In certain embodiments, the compositions, formulations, ophthalmic compositions, or ophthalmic screen compositions reduce oxidative stress associated with ultraviolet exposure through the combined activity of one or more ultraviolet-attenuating compounds and one or more flavonoids or polyphenolic compounds.
[0062] In certain embodiments, the composition, formulations, ophthalmic compositions, or ophthalmic screen compositions, s comprise ensulizole in combination with quercetin, resveratrol, curcumin, EGCG, rutin, luteolin, hyaluronic acid, sodium hyaluronate, brimonidine tartrate, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, tetryzoline hydrochloride, naphazoline hydrochloride, glycerin, or any combination thereof.
[0063] In certain embodiments, the compositions, formulations, ophthalmic compositions, or ophthalmic screen compositions provide simultaneous: ultraviolet attenuation, ocular lubrication, reduction of oxidative stress, reduction of ocular redness, improvement in tear-film stability, ocular hydration, cosmetic enhancement of the eye, ocular whitening, reduction in reactive oxygen species (ROS), epithelial protection, photoprotection, reduction of ocular photoaging, prolonged ocular surface residence time, or any combination thereof.
[0064] In certain embodiments, the compositions, formulations, ophthalmic compositions, or ophthalmic screen compositions further attenuate visible light, high-energy visible (HEV) light, blue light, infrared radiation, oxidative light stress, or any combination thereof.
[0065] In certain embodiments, the compositions, formulations, ophthalmic compositions, or ophthalmic screen compositions reduce or prevent ocular photoaging, ultraviolet-associated cosmetic ocular changes, conjunctival discoloration, ultraviolet-associated ocular surface degeneration, or any combination thereof.
[0066] In certain embodiments, the compositions, formulations, ophthalmic compositions, or ophthalmic screen compositions described herein reduce ultraviolet transmission to ocular tissues, reduce oxidative injury associated with ultraviolet radiation exposure, stabilize tear-film function, reduce conjunctival hyperemia, improve ocular comfort, improve ocular hydration, improve cosmetic appearance of the eye, improve ocular whitening, or any combination thereof.
[0067] In certain embodiments, the compositions, formulations, ophthalmic compositions, or ophthalmic screen compositions are formulated as ophthalmic solutions, emulsions, suspensions, gels, ointments, sprays, mists, films, inserts, nanoparticles, microparticles, liposomal formulations, sustained-release formulations, depot formulations, contact lens-associated formulations, biodegradable polymer formulations, micellar formulations, nanoemulsions, or any combination thereof.Attorney Docket No.56964-703601
[0068] Therapeutic Agents
[0069] In some embodiments, the compositions for ocular UV protection described herein comprises ensulizole and a second therapeutic agent. In some embodiments, the compositions for ocular UV protection described herein comprises ensulizole. In some embodiments, the compositions for ocular UV protection described herein comprises a second therapeutic agent.
[0070] In some embodiments, the compositions for ocular UV protection described herein comprises ensulizole (phenylbenzimidazole sulfonic acid “PBSA”, C13H10N2O3S, CAS no: 27503-81-7). In some embodiments, the ensulizole is represented by the structure ofHN
[0071] In some embodiments, the compositions for ocular UV protection described herein comprise at least 0.25 wt% ensulizole. In some embodiments, the compositions described herein comprise at most 15 wt% ensulizole.
[0072] In some embodiments, the compositions for ocular UV protection described herein comprise ensulizole at a range of about 0.25 wt% to about 15 wt%. In some embodiments, the compositions comprise ensulizole at a range of about 0.25 wt% to about 15.0 wt%, about 0.5 wt% to about 15.0 wt%, about 0.75 wt% to about 15.0 wt%, about 1.0 wt% to about 15.0 wt%, about 1.25 wt% to about 15.0 wt%, about 1.5 wt% to about 15.0 wt%, about 1.75 wt% to about 15.0 wt%, about 2.0 wt% to about 15.0 wt%, about 2.25 wt% to about 15.0 wt%, about 2.5 wt% to about 15.0 wt%, about 2.75 wt% to about 15.0 wt%, about 3.0 wt% to about 15.0 wt%, about 3.25 wt% to about 15.0 wt%, about 3.5 wt% to about 15.0 wt%, about 3.75 wt% to about 15.0 wt%, about 4.0 wt% to about 15.0 wt%, about 4.25 wt% to about 15.0 wt%, about 4.5 wt% to about 15.0 wt%, about 4.75 wt% to about 15.0 wt%, about 5.0 wt% to about 15.0 wt%, about 5.25 wt% to about 15.0 wt%, about 5.5 wt% to about 15.0 wt%, about 5.75 wt% to about 15.0 wt%, about 6.0 wt% to about 15.0 wt%, about 6.25 wt% to about 15.0 wt%, about 6.5 wt% to about 15.0 wt%, about 6.75 wt% to about 15.0 wt%, about 7.0 wt% to about 15.0 wt%, about 7.25 wt% to about 15.0 wt%, about 7.5 wt% to about 15.0 wt%, about 7.75 wt% to about 15.0 wt%, about 8.0 wt% to about 15.0 wt%, about 8.25 wt% to about 15.0 wt%, about 8.5 wt% to about 15.0 wt%, about 8.75 wt% to about 15.0 wt%, about 9.0 wt% to about 15.0 wt%, about 9.25 wt% to about 15.0 wt%, about 9.5 wt% to about 15.0 wt%, about 9.75 wt% to about 15.0 wt%, about 10.0 wt% to about 15.0 wt%, about 10.25 wt% to about 15.0 wt%, about 10.5 wt% to about 15.0 wt%, about 10.75 wt% to about 15.0 wt%, about 11.0 wt% to about 15.0 wt%, about 11.25 wt% to about 15.0 wt%, about 11.5 wt% to about 15.0 wt%, about 11.75 wt% to about 15.0 wt%, about 12.0 wt% to about 15.0 wt%, about 12.25 wt% to about 15.0 wt%, about 12.5 wt% toAttorney Docket No.56964-703601about 15.0 wt%, about 12.75 wt% to about 15.0 wt%, about 13.0 wt% to about 15.0 wt%, about 13.25 wt% to about 15.0 wt%, about 13.5 wt% to about 15.0 wt%, about 13.75 wt% to about 15.0 wt%, about 14.0 wt% to about 15.0 wt%, about 14.25 wt% to about 15.0 wt%, about 14.5 wt% to about 15.0 wt%, or about 14.75 wt% to about 15.0 wt%.
[0073] In some embodiments, the compositions for ocular UV protection described herein comprise ensulizole at a range of 0.25 wt% to 15 wt%. In some embodiments, the compositions comprise ensulizole at a range of 0.25 wt% to 15.0 wt%, 0.5 wt% to 15.0 wt%, 0.75 wt% to 15.0 wt%, 1.0 wt% to 15.0 wt%, 1.25 wt% to 15.0 wt%, 1.5 wt% to 15.0 wt%, 1.75 wt% to 15.0 wt%, 2.0 wt% to 15.0 wt%, 2.25 wt% to 15.0 wt%, 2.5 wt% to 15.0 wt%, 2.75 wt% to 15.0 wt%, 3.0 wt% to 15.0 wt%, 3.25 wt% to 15.0 wt%, 3.5 wt% to 15.0 wt%, 3.75 wt% to 15.0 wt%, 4.0 wt% to 15.0 wt%, 4.25 wt% to 15.0 wt%, 4.5 wt% to 15.0 wt%, 4.75 wt% to 15.0 wt%, 5.0 wt% to 15.0 wt%, 5.25 wt% to 15.0 wt%, 5.5 wt% to 15.0 wt%, 5.75 wt% to 15.0 wt%, 6.0 wt% to 15.0 wt%, 6.25 wt% to 15.0 wt%, 6.5 wt% to 15.0 wt%, 6.75 wt% to 15.0 wt%, 7.0 wt% to 15.0 wt%, 7.25 wt% to 15.0 wt%, 7.5 wt% to 15.0 wt%, 7.75 wt% to 15.0 wt%, 8.0 wt% to 15.0 wt%, 8.25 wt% to 15.0 wt%, 8.5 wt% to 15.0 wt%, 8.75 wt% to 15.0 wt%, 9.0 wt% to 15.0 wt%, 9.25 wt% to 15.0 wt%, 9.5 wt% to 15.0 wt%, 9.75 wt% to 15.0 wt%, 10.0 wt% to 15.0 wt%, 10.25 wt% to 15.0 wt%, 10.5 wt% to 15.0 wt%, 10.75 wt% to 15.0 wt%, 11.0 wt% to 15.0 wt%, 11.25 wt% to 15.0 wt%, 11.5 wt% to 15.0 wt%, 11.75 wt% to 15.0 wt%, 12.0 wt% to 15.0 wt%, 12.25 wt% to 15.0 wt%, 12.5 wt% to 15.0 wt%, 12.75 wt% to 15.0 wt%, 13.0 wt% to 15.0 wt%, 13.25 wt% to 15.0 wt%, 13.5 wt% to 15.0 wt%, 13.75 wt% to 15.0 wt%, 14.0 wt% to 15.0 wt%, 14.25 wt% to 15.0 wt%, 14.5 wt% to 15.0 wt%, or 14.75 wt% to 15.0 wt%.
[0074] In some embodiments, the compositions comprise ensulizole at about 0.25 wt%. In some embodiments, the compositions comprise ensulizole at about 0.50 wt%. In some embodiments, the compositions comprise ensulizole at about 0.75 wt%. In some embodiments, the compositions comprise ensulizole at about 1.00 wt%. In some embodiments, the compositions comprise ensulizole at about 1.25 wt%. In some embodiments, the compositions comprise ensulizole at about 1.50 wt%. In some embodiments, the compositions comprise ensulizole at about 1.75 wt%. In some embodiments, the compositions comprise ensulizole at about 2.00 wt%. In some embodiments, the compositions comprise ensulizole at about 2.25 wt%. In some embodiments, the compositions comprise ensulizole at about 2.50 wt%. In some embodiments, the compositions comprise ensulizole at about 2.75 wt%. In some embodiments, the compositions comprise ensulizole at about 3.00 wt%. In some embodiments, the compositions comprise ensulizole at about 3.25 wt%. In some embodiments, the compositions comprise ensulizole at about 3.50 wt%. In some embodiments, the compositions comprise ensulizole at about 3.75 wt%. In some embodiments, the compositions comprise ensulizole atAttorney Docket No.56964-703601about 4.00 wt%. In some embodiments, the compositions comprise ensulizole at about 4.25 wt%. In some embodiments, the compositions comprise ensulizole at about 4.50 wt%. In some embodiments, the compositions comprise ensulizole at about 4.75 wt%. In some embodiments, the compositions comprise ensulizole at about 5.00 wt%. In some embodiments, the compositions comprise ensulizole at about 5.25 wt%. In some embodiments, the compositions comprise ensulizole at about 5.50 wt%. In some embodiments, the compositions comprise ensulizole at about 5.75 wt%. In some embodiments, the compositions comprise ensulizole at about 6.00 wt%. In some embodiments, the compositions comprise ensulizole at about 6.25 wt%. In some embodiments, the compositions comprise ensulizole at about 6.50 wt%. In some embodiments, the compositions comprise ensulizole at about 6.75 wt%. In some embodiments, the compositions comprise ensulizole at about 7.00 wt%. In some embodiments, the compositions comprise ensulizole at about 7.25 wt%. In some embodiments, the compositions comprise ensulizole at about 7.50 wt%. In some embodiments, the compositions comprise ensulizole at about 7.75 wt%. In some embodiments, the compositions comprise ensulizole at 8.00 wt%. In some embodiments, the compositions comprise ensulizole at about 8.25 wt%. In some embodiments, the compositions comprise ensulizole at about 8.50 wt%. In some embodiments, the compositions comprise ensulizole at about 8.75 wt%. In some embodiments, the compositions comprise ensulizole at about 9.00 wt%. In some embodiments, the compositions comprise ensulizole at 9.25 wt%. In some embodiments, the compositions comprise ensulizole at about 9.50 wt%. In some embodiments, the compositions comprise ensulizole at about 9.75 wt%. In some embodiments, the compositions comprise ensulizole at about 10.00 wt%. In some embodiments, the compositions comprise ensulizole at about 10.25 wt%. In some embodiments, the compositions comprise ensulizole at about 10.50 wt%. In some embodiments, the compositions comprise ensulizole at about 10.75 wt%. In some embodiments, the compositions comprise ensulizole at about 11.00 wt%. In some embodiments, the compositions comprise ensulizole at about 11.25 wt%. In some embodiments, the compositions comprise ensulizole at about 11.50 wt%. In some embodiments, the compositions comprise ensulizole at about 11.75 wt%. In some embodiments, the compositions comprise ensulizole at about 12.00 wt%. In some embodiments, the compositions comprise ensulizole at about 12.25 wt%. In some embodiments, the compositions comprise ensulizole at about 12.50 wt%. In some embodiments, the compositions comprise ensulizole at about 12.75 wt%. In some embodiments, the compositions comprise ensulizole at about 13.00 wt%. In some embodiments, the compositions comprise ensulizole at about 13.25 wt%. In some embodiments, the compositions comprise ensulizole at about 13.50 wt%. In some embodiments, the compositions comprise ensulizole at about 13.75 wt%. In some embodiments, the compositions comprise ensulizole atAttorney Docket No.56964-703601about 14.00 wt%. In some embodiments, the compositions comprise ensulizole at about 14.25 wt%. In some embodiments, the compositions comprise ensulizole at about 14.50 wt%. In some embodiments, the compositions comprise ensulizole at about 14.75 wt%. In some embodiments, the compositions comprise ensulizole at about 15.00 wt%.
[0075] In some embodiments, the compositions comprise ensulizole at 0.25 wt%. In some embodiments, the compositions comprise ensulizole at 0.50 wt%. In some embodiments, the compositions comprise ensulizole at 0.75 wt%. In some embodiments, the compositions comprise ensulizole at 1.00 wt%. In some embodiments, the compositions comprise ensulizole at 1.25 wt%. In some embodiments, the compositions comprise ensulizole at 1.50 wt%. In some embodiments, the compositions comprise ensulizole at 1.75 wt%. In some embodiments, the compositions comprise ensulizole at 2.00 wt%. In some embodiments, the compositions comprise ensulizole at 2.25 wt%. In some embodiments, the compositions comprise ensulizole at 2.50 wt%. In some embodiments, the compositions comprise ensulizole at 2.75 wt%. In some embodiments, the compositions comprise ensulizole at 3.00 wt%. In some embodiments, the compositions comprise ensulizole at 3.25 wt%. In some embodiments, the compositions comprise ensulizole at 3.50 wt%. In some embodiments, the compositions comprise ensulizole at 3.75 wt%. In some embodiments, the compositions comprise ensulizole at 4.00 wt%. In some embodiments, the compositions comprise ensulizole at 4.25 wt%. In some embodiments, the compositions comprise ensulizole at 4.50 wt%. In some embodiments, the compositions comprise ensulizole at 4.75 wt%. In some embodiments, the compositions comprise ensulizole at 5.00 wt%. In some embodiments, the compositions comprise ensulizole at 5.25 wt%. In some embodiments, the compositions comprise ensulizole at 5.50 wt%. In some embodiments, the compositions comprise ensulizole at 5.75 wt%. In some embodiments, the compositions comprise ensulizole at 6.00 wt%. In some embodiments, the compositions comprise ensulizole at 6.25 wt%. In some embodiments, the compositions comprise ensulizole at 6.50 wt%. In some embodiments, the compositions comprise ensulizole at 6.75 wt%. In some embodiments, the compositions comprise ensulizole at 7.00 wt%. In some embodiments, the compositions comprise ensulizole at 7.25 wt%. In some embodiments, the compositions comprise ensulizole at 7.50 wt%. In some embodiments, the compositions comprise ensulizole at 7.75 wt%. In some embodiments, the compositions comprise ensulizole at 8.00 wt%. In some embodiments, the compositions comprise ensulizole at 8.25 wt%. In some embodiments, the compositions comprise ensulizole at 8.50 wt%. In some embodiments, the compositions comprise ensulizole at 8.75 wt%. In some embodiments, the compositions comprise ensulizole at 9.00 wt%. In some embodiments, the compositions comprise ensulizole at 9.25 wt%. In some embodiments, the compositions comprise ensulizole at 9.50 wt%. In some embodiments, the compositionsAttorney Docket No.56964-703601comprise ensulizole at 9.75 wt%. In some embodiments, the compositions comprise ensulizole at 10.00 wt%. In some embodiments, the compositions comprise ensulizole at 10.25 wt%. In some embodiments, the compositions comprise ensulizole at 10.50 wt%. In some embodiments, the compositions comprise ensulizole at 10.75 wt%. In some embodiments, the compositions comprise ensulizole at 11.00 wt%. In some embodiments, the compositions comprise ensulizole at 11.25 wt%. In some embodiments, the compositions comprise ensulizole at 11.50 wt%. In some embodiments, the compositions comprise ensulizole at 11.75 wt%. In some embodiments, the compositions comprise ensulizole at 12.00 wt%. In some embodiments, the compositions comprise ensulizole at 12.25 wt%. In some embodiments, the compositions comprise ensulizole at 12.50 wt%. In some embodiments, the compositions comprise ensulizole at 12.75 wt%. In some embodiments, the compositions comprise ensulizole at 13.00 wt%. In some embodiments, the compositions comprise ensulizole at 13.25 wt%. In some embodiments, the compositions comprise ensulizole at 13.50 wt%. In some embodiments, the compositions comprise ensulizole at 13.75 wt%. In some embodiments, the compositions comprise ensulizole at 14.00 wt%. In some embodiments, the compositions comprise ensulizole at 14.25 wt%. In some embodiments, the compositions comprise ensulizole at 14.50 wt%. In some embodiments, the compositions comprise ensulizole at 14.75 wt%. In some embodiments, the compositions comprise ensulizole at 15.00 wt%.
[0076] In some embodiments the compositions for ocular UV protection described herein comprise a second therapeutic agent. In some embodiments, the second therapeutic agent comprises salicylic acid (“2-Hydroxybenzoic acid”, “2-Carboxyphenol”, C7H6O3, CAS #:69-72-7), niacinamide (“Nicotinamide”, “3-pyridinecarboxamide niacinamide”, C6H6N2O, CAS#:98-92-0), commercially available eyedrop formulations comprising one or more active ingredients, or the one or more active ingredients contained in commercially available eyedrop formulations. In some embodiments, the second therapeutic agent comprises salicylic acid. In some embodiments, the second therapeutic agent comprises niacinamide. In some embodiments, the second therapeutic agent comprises commercially available eyedrop formulations comprising one or more active ingredients. In some embodiments, the second therapeutic agent comprises the one or more active ingredients contained in commercially available eyedrop formulations. In some embodiments, the second therapeutic agent is selected from povidone, glycerin, polyethylene glycol 300, polyethylene glycol 400, carboxymethylcellulose, Polysorbate 80, light mineral oil, mineral oil, naphazoline hydrochloride, ketotifen, pheniramine maleate, ketorolac tromethamine, prednisolone acetate, alcaftadine, brimonidine tartrate, timolol maleate, bimatoprost, Brimonidine tartrate, Cyclosporine, Pilocarpine hydrochloride, ketorolac trometamol, antazoline phosphate, fluoromethoIone, and carmellose sodium, or any combinationAttorney Docket No.56964-703601thereof. In some embodiments, the second therapeutic agent is povidone, glycerin, polyethylene glycol 300, polyethylene glycol 400, carboxymethylcellulose, Polysorbate 80, light mineral oil, mineral oil, naphazoline hydrochloride, ketotifen, pheniramine maleate, ketorolac tromethamine, prednisolone acetate, alcaftadine, brimonidine tartrate, timolol maleate, bimatoprost, Brimonidine tartrate, Cyclosporine, Pilocarpine hydrochloride, ketorolac trometamol, antazoline phosphate, fluoromethoIone, carmellose sodium, or any combination thereof.
[0077] In some embodiments, the second therapeutic agent comprises the commercially available eyedrop formulations comprising one or more active ingredients. Non-limiting examples of commercially available eyedrop formulations comprising one or more active ingredients include: Soothe® Dry Eye [Active ingredient: Povidone (1.25%)]; Biotrue® Hydration Boost Lubricant Eye Drops [Active ingredient: Glycerin (0.5%)]; Blink® Triple Care Lubricating Eye Drops [Active ingredient: Polyethylene Glycol 400 (0.25%)]; Blink GelTears® Lubricating Eye Drops [Active ingredient: Polyethylene Glycol 400 (0.25%)]; Soothe® XP Emollient Eye Drops [Active ingredients: Light mineral oil (1.0%), Mineral oil (4.5%)];Advanced Eye Relief / Redness Instant Relief [Active ingredients: Naphazoline hydrochloride (0.012%) and Polyethylene glycol 300 (0.2%)]; Alaway® Antihistamine Eye Drops [Active ingredient: Ketotifen (0.025%)]; Opcon-A® Allergy Relief Eye Drops [Active ingredients: Naphazoline HC1 (0.02675%), Pheniramine Maleate (0.135%)]; Acuvail® [Active ingredient: Ketorolac tromethamine (0.45%)]; Pred Forte® [Active ingredient: Prednisolone acetate (microfine suspension) (1%)]; Lastacaft® [Active ingredient: Alcaftadine (0.25%)]; Combigan® [Active ingredients: Brimonidine tartrate / Timolol maleate ophthalmic solution (0.2% / 0.5%)]; Lumigan® [Active ingredient: Bimatoprost (0.01%)]; Alphagan® [Active ingredients:Brimonidine tartrate 0.1% (1 mg / mL) or 0.15% (1.5 mg / mL)]; Refresh® Digital [Active ingredients: Carboxymethylcellulose (CMC) (0.5%), Glycerin (1%), Polysorbate 80 (0.5%); Refresh® Relieva® PF Xtra [Active ingredients: Carboxymethylcellulose (CMC) (0.5%), Glycerin (0.9%)]; Refresh Mega 3® [Active ingredients: Carboxymethylcellulose (CMC) (0.5%), Glycerin (1%), Polysorbate 80 (0.5%); Refresh Optive® [Active ingredients:Carboxymethylcellulose (CMC) (1%), Glycerin (0.9%)]; Resistasis® [Active ingredient:Cyclosporine (0.5%)]; Vuity® [Active ingredient: Pilocarpine hydrochloride (1.25%)]; Acular® [Active ingredient: Ketorolac trometamol (5%)]; Albalon® [Active ingredient: Naphazoline hydrochloride]; Albalon A® [Active ingredients: Naphazoline hydrochloride (0.05%), Antazoline phosphate (0.5%)]; FML Liquifilm® [Active ingredient: FluoromethoIone (1.0%)]; Celluvisc® [Active ingredient: Carmellose sodium (0.5% / 1.0%)]; or Ganafort® [Active ingredients: Bimatoprost and Timolol (0.3 mg / mL / 0.5 mg / mL)].Attorney Docket No.56964-703601
[0078] In some embodiments, the second therapeutic agent comprises Soothe® Dry Eye, Biotrue® Hydration Boost Lubricant Eye Drops, Blink® Triple Care Lubricating Eye Drops, Blink GelTears® Lubricating Eye Drops, Soothe® XP Emollient Eye Drops, Advanced Eye Relief / Redness Instant Relief, Alaway® Antihistamine Eye Drops, Opcon-A® Allergy Relief Eye Drops, Acuvail®, Pred Forte®, Lastacaft®, Combigan®, Lumigan®, Alphagan®, Refresh® Digital, Refresh® Relieva® PF Xtra, RefreshMega 3®, Refresh Optive ®, Resistasis®, Vuity®, Acular®, Albalon®, Albalon A®, FML Liquifilm® eyedrops, Celluvisc®, or Ganafort®. In some embodiments, the second therapeutic agent comprises Soothe® Dry Eye. In some embodiments, the second therapeutic agent comprises Biotrue® Hydration Boost Lubricant Eye Drops. In some embodiments, the second therapeutic agent comprises Blink® Triple Care Lubricating Eye Drops. In some embodiments, the second therapeutic agent comprises Blink GelTears® Lubricating Eye Drops. In some embodiments, the second therapeutic agent comprises Soothe® XP Emollient Eye Drops. In some embodiments, the second therapeutic agent comprises Advanced Eye Relief / Redness Instant Relief. In some embodiments, the second therapeutic agent comprises Alaway® Antihistamine Eye Drops. In some embodiments, the second therapeutic agent comprises Opcon-A® Allergy Relief Eye Drops. In some embodiments, the second therapeutic agent comprises Acuvail®. In some embodiments, the second therapeutic agent comprises Pred Forte®. In some embodiments, the second therapeutic agent comprises Lastacaft®. In some embodiments, the second therapeutic agent comprises Combigan®. In some embodiments, the second therapeutic agent comprises Lumigan®. In some embodiments, the second therapeutic agent comprises Alphagan®. In some embodiments, the second therapeutic agent comprises Refresh® Digital. In some embodiments, the second therapeutic agent comprises Refresh® Relieva® PF Xtra. In some embodiments, the second therapeutic agent comprises RefreshMega 3®. In some embodiments, the second therapeutic agent comprises Refresh Optive®. In some embodiments, the second therapeutic agent comprises Resistasis®. In some embodiments, the second therapeutic agent comprises Vuity®. In some embodiments, the second therapeutic agent comprises Acular®. In some embodiments, the second therapeutic agent comprises Albalon®. In some embodiments, the second therapeutic agent comprises Albalon A®. In some embodiments, the second therapeutic agent comprises FML Liquifilm® eyedrops. In some embodiments, the second therapeutic agent comprises Celluvisc®. In some embodiments, the second therapeutic agent comprises Ganafort®.
[0079] In some embodiments, the second therapeutic agent comprises the one or more active ingredients contained in the commercially available eyedrop formulations. In some embodiments, the second therapeutic agent is selected from the group consisting of: povidone, glycerin, polyethylene glycol 400, light mineral oil, mineral oil, naphazoline hydrochloride, polyethyleneAttorney Docket No.56964-703601glycol 300, ketotifen, pheniramine maleate, ketorolac tromethamine, prednisolone acetate, alcaftadine, brimonidine tartrate, timolol maleate, bimatoprost, carboxymethylcellulose (CMC), polysorbate 80, cyclosporine, pilocarpine hydrochloride, antazoline phosphate, fluoromethoIone, carmellose sodium, and timolol. In some embodiments, the second therapeutic agent comprises povidone. In some embodiments, the second therapeutic agent comprises glycerin. In some embodiments, the second therapeutic agent comprises polyethylene glycol 400. In some embodiments, the second therapeutic agent comprises light mineral oil. In some embodiments, the second therapeutic agent comprises mineral oil. In some embodiments, the second therapeutic agent comprises naphazoline hydrochloride. In some embodiments, the second therapeutic agent comprises polyethylene glycol 300. In some embodiments, the second therapeutic agent comprises ketotifen. In some embodiments, the second therapeutic agent comprises pheniramine maleate. In some embodiments, the second therapeutic agent comprises ketorolac tromethamine. In some embodiments, the second therapeutic agent comprises prednisolone acetate. In some embodiments, the second therapeutic agent comprises alcaftadine. In some embodiments, the second therapeutic agent comprises brimonidine tartrate. In some embodiments, the second therapeutic agent comprises timolol maleate. In some embodiments, the second therapeutic agent comprises bimatoprost. In some embodiments, the second therapeutic agent comprises carboxymethylcellulose (CMC). In some embodiments, the second therapeutic agent comprises polysorbate 80. In some embodiments, the second therapeutic agent comprises cyclosporine. In some embodiments, the second therapeutic agent comprises pilocarpine hydrochloride. In some embodiments, the second therapeutic agent comprises antazoline phosphate. In some embodiments, the second therapeutic agent comprises fluoromethoIone. In some embodiments, the second therapeutic agent comprises carmellose sodium. In some embodiments, the second therapeutic agent comprises timolol.
[0080] In some embodiments, the second therapeutic agent is selected from glycerin, propylene glycol, Soothe® Dry Eye, Biotrue® Hydration Boost Lubricant Eye Drops, Blink® Triple Care Lubricating Eye Drops, Blink GelTears® Lubricating Eye Drops, Soothe® XP Emollient Eye Drops, Advanced Eye Relief / Redness Instant Relief, Alaway® Antihistamine Eye Drops, Opcon-A® Allergy Relief Eye Drops, Acuvail®, Pred Forte®, Lastacaft®, Combigan®, Lumigan®, Alphagan®, Refresh® Digital, Refresh® Relieva® PF Xtra, RefreshMega 3®, Refresh Optive ®, Resistasis®, Vuity®, Acular®, Albalon®, Albalon A®, FML Liquifilm® eyedrops, Celluvisc®, and Ganafort®.
[0081] Vehicle
[0082] In some embodiments, the compositions for ocular UV protection described herein may further comprise the use of eyedrops that contain a liquid vehicle base. Non-limiting examples ofAttorney Docket No.56964-703601liquid vehicle bases appropriate for eyedrop formulations include sterile water for injection, balanced salt solutions such as phosphate-buffered saline, isotonic saline solutions, hypotonic or hypertonic aqueous solutions, and preservative-free aqueous vehicles. Buffered aqueous solutions may be used to maintain pH stability, including ophthalmic-grade artificial tears.Ophthalmic-grade oils or emulsions may be employed for emollient formulations, while polymer-based vehicles such as polyvinyl alcohol, polyethylene glycol, carboxymethylcellulose (CMC), or hydroxypropyl methylcellulose solutions may serve as viscosity enhancers to improve ocular retention and comfort. Preservatives may be included in these formulations to prevent microbial contamination and prolong shelflife, though preservative-free options may be more appropriate in certain cases to reduce ocular irritation.
[0083] Formulations
[0084] In some embodiments, the formulations described herein comprise about 0.25 wt% to about 15.0 wt% of ensulizole and a second agent.
[0085] In some embodiments, the formulation comprises 0.25 wt% comprises ensulizole at a range of about 0.25 wt% to about 15.0 wt%, about 0.5 wt% to about 15.0 wt%, about 0.75 wt% to about 15.0 wt%, about 1.0 wt% to about 15.0 wt%, about 1.25 wt% to about 15.0 wt%, about 1.5 wt% to about 15.0 wt%, about 1.75 wt% to about 15.0 wt%, about 2.0 wt% to about 15.0 wt%, about 2.25 wt% to about 15.0 wt%, about 2.5 wt% to about 15.0 wt%, about 2.75 wt% to about 15.0 wt%, about 3.0 wt% to about 15.0 wt%, about 3.25 wt% to about 15.0 wt%, about 3.5 wt% to about 15.0 wt%, about 3.75 wt% to about 15.0 wt%, about 4.0 wt% to about 15.0 wt%, about 4.25 wt% to about 15.0 wt%, about 4.5 wt% to about 15.0 wt%, about 4.75 wt% to about 15.0 wt%, about 5.0 wt% to about 15.0 wt%, about 5.25 wt% to about 15.0 wt%, about 5.5 wt% to about 15.0 wt%, about 5.75 wt% to about 15.0 wt%, about 6.0 wt% to about 15.0 wt%, about 6.25 wt% to about 15.0 wt%, about 6.5 wt% to about 15.0 wt%, about 6.75 wt% to about 15.0 wt%, about 7.0 wt% to about 15.0 wt%, about 7.25 wt% to about 15.0 wt%, about 7.5 wt% to about 15.0 wt%, about 7.75 wt% to about 15.0 wt%, about 8.0 wt% to about 15.0 wt%, about 8.25 wt% to about 15.0 wt%, about 8.5 wt% to about 15.0 wt%, about 8.75 wt% to about 15.0 wt%, about 9.0 wt% to about 15.0 wt%, about 9.25 wt% to about 15.0 wt%, about 9.5 wt% to about 15.0 wt%, about 9.75 wt% to about 15.0 wt%, about 10.0 wt% to about 15.0 wt%, about 10.25 wt% to about 15.0 wt%, about 10.5 wt% to about 15.0 wt%, about 10.75 wt% to about 15.0 wt%, about 11.0 wt% to about 15.0 wt%, about 11.25 wt% to about 15.0 wt%, about 11.5 wt% to about 15.0 wt%, about 11.75 wt% to about 15.0 wt%, about 12.0 wt% to about 15.0 wt%, about 12.25 wt% to about 15.0 wt%, about 12.5 wt% to about 15.0 wt%, about 12.75 wt% to about 15.0 wt%, about 13.0 wt% to about 15.0 wt%, about 13.25 wt% to about 15.0 wt%, about 13.5 wt% to about 15.0 wt%, about 13.75 wt% to about 15.0 wt%, about 14.0 wt% to about 15.0 wt%, aboutAttorney Docket No.56964-70360114.25 wt% to about 15.0 wt%, about 14.5 wt% to about 15.0 wt%, or about 14.75 wt% to about 15.0 wt%.
[0086] In some embodiments, the formulation comprises ensulizole at a range of 0.25 wt% to 15.0 wt%, 0.5 wt% to 15.0 wt%, 0.75 wt% to 15.0 wt%, 1.0 wt% to 15.0 wt%, 1.25 wt% to 15.0 wt%, 1.5 wt% to 15.0 wt%, 1.75 wt% to 15.0 wt%, 2.0 wt% to 15.0 wt%, 2.25 wt% to 15.0 wt%, 2.5 wt% to 15.0 wt%, 2.75 wt% to 15.0 wt%, 3.0 wt% to 15.0 wt%, 3.25 wt% to 15.0 wt%, 3.5 wt% to 15.0 wt%, 3.75 wt% to 15.0 wt%, 4.0 wt% to 15.0 wt%, 4.25 wt% to 15.0 wt%, 4.5 wt% to 15.0 wt%, 4.75 wt% to 15.0 wt%, 5.0 wt% to 15.0 wt%, 5.25 wt% to 15.0 wt%, 5.5 wt% to 15.0 wt%, 5.75 wt% to 15.0 wt%, 6.0 wt% to 15.0 wt%, 6.25 wt% to 15.0 wt%, 6.5 wt% to 15.0 wt%, 6.75 wt% to 15.0 wt%, 7.0 wt% to 15.0 wt%, 7.25 wt% to 15.0 wt%, 7.5 wt% to 15.0 wt%, 7.75 wt% to 15.0 wt%, 8.0 wt% to 15.0 wt%, 8.25 wt% to 15.0 wt%, 8.5 wt% to 15.0 wt%, 8.75 wt% to 15.0 wt%, 9.0 wt% to 15.0 wt%, 9.25 wt% to 15.0 wt%, 9.5 wt% to 15.0 wt%, 9.75 wt% to 15.0 wt%, 10.0 wt% to 15.0 wt%, 10.25 wt% to 15.0 wt%, 10.5 wt% to 15.0 wt%, 10.75 wt% to 15.0 wt%, 11.0 wt% to 15.0 wt%, 11.25 wt% to 15.0 wt%, 11.5 wt% to 15.0 wt%, 11.75 wt% to 15.0 wt%, 12.0 wt% to 15.0 wt%, 12.25 wt% to 15.0 wt%, 12.5 wt% to 15.0 wt%, 12.75 wt% to 15.0 wt%, 13.0 wt% to 15.0 wt%, 13.25 wt% to 15.0 wt%, 13.5 wt% to 15.0 wt%, 13.75 wt% to 15.0 wt%, 14.0 wt% to 15.0 wt%, 14.25 wt% to 15.0 wt%, 14.5 wt% to 15.0 wt%, or 14.75 wt% to 15.0 wt%.
[0087] In some embodiments, the formulation comprises 0.25 wt% ensulizole. In some embodiments, the formulation comprises ensulizole at about 0.50 wt%. In some embodiments, the formulation comprises ensulizole at about 0.75 wt%. In some embodiments, the formulation comprises ensulizole at about 1.00 wt%. In some embodiments, the formulation comprises ensulizole at about 1.25 wt%. In some embodiments, the formulation comprises ensulizole at about 1.50 wt%. In some embodiments, the formulation comprises ensulizole at about 1.75 wt%. In some embodiments, the formulation comprises ensulizole at about 2.00 wt%. In some embodiments, the formulation comprises ensulizole at about 2.25 wt%. In some embodiments, the formulation comprises ensulizole at about 2.50 wt%. In some embodiments, the formulation comprises ensulizole at about 2.75 wt%. In some embodiments, the formulation comprises ensulizole at about 3.00 wt%. In some embodiments, the formulation comprises ensulizole at about 3.25 wt%. In some embodiments, the formulation comprises ensulizole at about 3.50 wt%. In some embodiments, the formulation comprises ensulizole at about 3.75 wt%. In some embodiments, the formulation comprises ensulizole at about 4.00 wt%. In some embodiments, the formulation comprises ensulizole at about 4.25 wt%. In some embodiments, the formulation comprises ensulizole at about 4.50 wt%. In some embodiments, the formulation comprises ensulizole at about 4.75 wt%. In some embodiments, the formulation comprises ensulizole atAttorney Docket No.56964-703601about 5.00 wt%. In some embodiments, the formulation comprises ensulizole at about 5.25 wt%. In some embodiments, the formulation comprises ensulizole at about 5.50 wt%. In some embodiments, the formulation comprises ensulizole at about 5.75 wt%. In some embodiments, the formulation comprises ensulizole at about 6.00 wt%. In some embodiments, the formulation comprises ensulizole at about 6.25 wt%. In some embodiments, the formulation comprises ensulizole at about 6.50 wt%. In some embodiments, the formulation comprises ensulizole at about 6.75 wt%. In some embodiments, the formulation comprises ensulizole at about 7.00 wt%. In some embodiments, the formulation comprises ensulizole at about 7.25 wt%. In some embodiments, the formulation comprises ensulizole at about 7.50 wt%. In some embodiments, the formulation comprises ensulizole at about 7.75 wt%. In some embodiments, the formulation comprises ensulizole at 8.00 wt%. In some embodiments, the formulation comprises ensulizole at about 8.25 wt%. In some embodiments, the formulation comprises ensulizole at about 8.50 wt%. In some embodiments, the formulation comprises ensulizole at about 8.75 wt%. In some embodiments, the formulation comprises ensulizole at about 9.00 wt%. In some embodiments, the formulation comprises ensulizole at 9.25 wt%. In some embodiments, the formulation comprises ensulizole at about 9.50 wt%. In some embodiments, the formulation comprises ensulizole at about 9.75 wt%. In some embodiments, the formulation comprises ensulizole at about 10.00 wt%. In some embodiments, the formulation comprises ensulizole at about 10.25 wt%. In some embodiments, the formulation comprises ensulizole at about 10.50 wt%. In some embodiments, the formulation comprises ensulizole at about 10.75 wt%. In some embodiments, the formulation comprises ensulizole at about 11.00 wt%. In some embodiments, the formulation comprises ensulizole at about 11.25 wt%. In some embodiments, the formulation comprises ensulizole at about 11.50 wt%. In some embodiments, the formulation comprises ensulizole at about 11.75 wt%. In some embodiments, the formulation comprises ensulizole at about 12.00 wt%. In some embodiments, the formulation comprises ensulizole at about 12.25 wt%. In some embodiments, the formulation comprises ensulizole at about 12.50 wt%. In some embodiments, the formulation comprises ensulizole at about 12.75 wt%. In some embodiments, the formulation comprises ensulizole at about 13.00 wt%. In some embodiments, the formulation comprises ensulizole at about 13.25 wt%. In some embodiments, the formulation comprises ensulizole at about 13.50 wt%. In some embodiments, the formulation comprises ensulizole at about 13.75 wt%. In some embodiments, the formulation comprises ensulizole at about 14.00 wt%. In some embodiments, the formulation comprises ensulizole at about 14.25 wt%. In some embodiments, the formulation comprises ensulizole at about 14.50 wt%. In some embodiments, the formulation comprises ensulizole at about 14.75 wt%. In some embodiments, the formulation comprises ensulizole at about 15.00 wt%.Attorney Docket No.56964-703601
[0088] In some embodiments, the formulation comprises 0.25 wt% ensulizole. In some embodiments, the formulation comprises ensulizole at 0.50 wt%. In some embodiments, the formulation comprises ensulizole at 0.75 wt%. In some embodiments, the formulation comprises ensulizole at 1.00 wt%. In some embodiments, the formulation comprises ensulizole at 1.25 wt%. In some embodiments, the formulation comprises ensulizole at 1.50 wt%. In some embodiments, the formulation comprises ensulizole at 1.75 wt%. In some embodiments, the formulation comprises ensulizole at 2.00 wt%. In some embodiments, the formulation comprises ensulizole at 2.25 wt%. In some embodiments, the formulation comprises ensulizole at 2.50 wt%. In some embodiments, the formulation comprises ensulizole at 2.75 wt%. In some embodiments, the formulation comprises ensulizole at 3.00 wt%. In some embodiments, the formulation comprises ensulizole at 3.25 wt%. In some embodiments, the formulation comprises ensulizole at 3.50 wt%. In some embodiments, the formulation comprises ensulizole at 3.75 wt%. In some embodiments, the formulation comprises ensulizole at 4.00 wt%. In some embodiments, the formulation comprises ensulizole at 4.25 wt%. In some embodiments, the formulation comprises ensulizole at 4.50 wt%. In some embodiments, the formulation comprises ensulizole at 4.75 wt%. In some embodiments, the formulation comprises ensulizole at 5.00 wt%. In some embodiments, the formulation comprises ensulizole at 5.25 wt%. In some embodiments, the formulation comprises ensulizole at 5.50 wt%. In some embodiments, the formulation comprises ensulizole at 5.75 wt%. In some embodiments, the formulation comprises ensulizole at 6.00 wt%. In some embodiments, the formulation comprises ensulizole at 6.25 wt%. In some embodiments, the formulation comprises ensulizole at 6.50 wt%. In some embodiments, the formulation comprises ensulizole at 6.75 wt%. In some embodiments, the formulation comprises ensulizole at 7.00 wt%. In some embodiments, the formulation comprises ensulizole at 7.25 wt%. In some embodiments, the formulation comprises ensulizole at 7.50 wt%. In some embodiments, the formulation comprises ensulizole at 7.75 wt%. In some embodiments, the formulation comprises ensulizole at 8.00 wt%. In some embodiments, the formulation comprises ensulizole at 8.25 wt%. In some embodiments, the formulation comprises ensulizole at 8.50 wt%. In some embodiments, the formulation comprises ensulizole at 8.75 wt%. In some embodiments, the formulation comprises ensulizole at 9.00 wt%. In some embodiments, the formulation comprises ensulizole at 9.25 wt%. In some embodiments, the formulation comprises ensulizole at 9.50 wt%. In some embodiments, the formulation comprises ensulizole at 9.75 wt%. In some embodiments, the formulation comprises ensulizole at 10.00 wt%. In some embodiments, the formulation comprises ensulizole at 10.25 wt%. In some embodiments, the formulation comprises ensulizole at 10.50 wt%. In some embodiments, the formulation comprises ensulizole at 10.75 wt%. In some embodiments, the formulation comprises ensulizole at 11.00 wt%. In some embodiments, the formulationAttorney Docket No.56964-703601comprises ensulizole at 11.25 wt%. In some embodiments, the formulation comprises ensulizole at 11.50 wt%. In some embodiments, the formulation comprises ensulizole at 11.75 wt%. In some embodiments, the formulation comprises ensulizole at 12.00 wt%. In some embodiments, the formulation comprises ensulizole at 12.25 wt%. In some embodiments, the formulation comprises ensulizole at 12.50 wt%. In some embodiments, the formulation comprises ensulizole at 12.75 wt%. In some embodiments, the formulation comprises ensulizole at 13.00 wt%. In some embodiments, the formulation comprises ensulizole at 13.25 wt%. In some embodiments, the formulation comprises ensulizole at 13.50 wt%. In some embodiments, the formulation comprises ensulizole at 13.75 wt%. In some embodiments, the formulation comprises ensulizole at 14.00 wt%. In some embodiments, the formulation comprises ensulizole at 14.25 wt%. In some embodiments, the formulation comprises ensulizole at 14.50 wt%. In some embodiments, the formulation comprises ensulizole at 14.75 wt%. In some embodiments, the formulation comprises ensulizole at 15.00 wt%.
[0089] In some embodiments, the second therapeutic agent is selected from povidone, glycerin, polyethylene glycol 300, polyethylene glycol 400, carboxymethylcellulose, Polysorbate 80, light mineral oil, mineral oil, naphazoline hydrochloride, ketotifen, pheniramine maleate, ketorolac tromethamine, prednisolone acetate, alcaftadine, brimonidine tartrate, timolol maleate, bimatoprost, Brimonidine tartrate, Cyclosporine, Pilocarpine hydrochloride, ketorolac trometamol, antazoline phosphate, fluorometholone, and carmellose sodium, or any combination thereof. In some embodiments, the second therapeutic agent is povidone, glycerin, polyethylene glycol 300, polyethylene glycol 400, carboxymethylcellulose, Polysorbate 80, light mineral oil, mineral oil, naphazoline hydrochloride, ketotifen, pheniramine maleate, ketorolac tromethamine, prednisolone acetate, alcaftadine, brimonidine tartrate, timolol maleate, bimatoprost, Brimonidine tartrate, Cyclosporine, Pilocarpine hydrochloride, ketorolac trometamol, antazoline phosphate, fluorometholone, carmellose sodium, or any combination thereof.
[0090] In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and glycerin. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and propylene glycol. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and Soothe® Dry Eye. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and Biotrue® Hydration Boost Lubricant Eye Drops. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and Blink® Triple Care Lubricating Eye Drops. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and Blink GelTears® Lubricating Eye Drops. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and Soothe® XP Emollient Eye Drops.Attorney Docket No.56964-703601In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and Advanced Eye Relief / Redness Instant Relief. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and Alaway® Antihistamine Eye Drops. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and Opcon-A® Allergy Relief Eye Drops. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and Acuvail®. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and Pred Forte®. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and Lastacaft®. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and Combigan®. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and Lumigan®. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and Alphagan®. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and Refresh® Digital. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and Refresh® Relieva® PF Xtra. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and RefreshMega 3®. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and Refresh Optive®. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and Resistasis®. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and Vuity®. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and Acular®. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and Albalon®. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and Albalon A®. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and FML Liquifilm® eyedrops. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and Celluvisc®. In some embodiments, the formulation comprises about 0.25 wt% to about 15 wt% of ensulizole and Ganafort®.
[0091] In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and glycerin. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and propylene glycol. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and Soothe® Dry Eye. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and Biotrue® Hydration Boost Lubricant Eye Drops. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and Blink® Triple Care Lubricating Eye Drops. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and Blink GelTears® Lubricating Eye Drops. In some embodiments, the formulation comprises about 0.25Attorney Docket No.56964-703601wt% of ensulizole and Soothe® XP Emollient Eye Drops. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and Advanced Eye Relief / Redness Instant Relief. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and Alaway® Antihistamine Eye Drops. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and Opcon-A® Allergy Relief Eye Drops. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and Acuvail®. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and Pred Forte®. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and Lastacaft®. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and Combigan®. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and Lumigan®. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and Alphagan®. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and Refresh® Digital. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and Refresh® Relieva® PF Xtra. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and RefreshMega 3®. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and Refresh Optive®. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and Resistasis®. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and Vuity®. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and Acular®. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and Albalon®. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and Albalon A®. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and FML Liquifilm® eyedrops. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and Celluvisc®. In some embodiments, the formulation comprises about 0.25 wt% of ensulizole and Ganafort®.
[0092] Ophthalmic Compositions
[0093] In some embodiments, the ophthalmic compositions described herein comprise about 0.25 wt% to about 15.0 wt% of ensulizole and a second agent.
[0094] In some embodiments, the ophthalmic composition comprises 0.25 wt% comprises ensulizole at a range of about 0.25 wt% to about 15.0 wt%, about 0.5 wt% to about 15.0 wt%, about 0.75 wt% to about 15.0 wt%, about 1.0 wt% to about 15.0 wt%, about 1.25 wt% to about 15.0 wt%, about 1.5 wt% to about 15.0 wt%, about 1.75 wt% to about 15.0 wt%, about 2.0 wt% to about 15.0 wt%, about 2.25 wt% to about 15.0 wt%, about 2.5 wt% to about 15.0 wt%, about 2.75 wt% to about 15.0 wt%, about 3.0 wt% to about 15.0 wt%, about 3.25 wt% to about 15.0 wt%, about 3.5 wt% to about 15.0 wt%, about 3.75 wt% to about 15.0 wt%, about 4.0 wt% to about 15.0 wt%, about 4.25 wt% to about 15.0 wt%, about 4.5 wt% to about 15.0 wt%, aboutAttorney Docket No.56964-7036014.75 wt% to about 15.0 wt%, about 5.0 wt% to about 15.0 wt%, about 5.25 wt% to about 15.0 wt%, about 5.5 wt% to about 15.0 wt%, about 5.75 wt% to about 15.0 wt%, about 6.0 wt% to about 15.0 wt%, about 6.25 wt% to about 15.0 wt%, about 6.5 wt% to about 15.0 wt%, about 6.75 wt% to about 15.0 wt%, about 7.0 wt% to about 15.0 wt%, about 7.25 wt% to about 15.0 wt%, about 7.5 wt% to about 15.0 wt%, about 7.75 wt% to about 15.0 wt%, about 8.0 wt% to about 15.0 wt%, about 8.25 wt% to about 15.0 wt%, about 8.5 wt% to about 15.0 wt%, about 8.75 wt% to about 15.0 wt%, about 9.0 wt% to about 15.0 wt%, about 9.25 wt% to about 15.0 wt%, about 9.5 wt% to about 15.0 wt%, about 9.75 wt% to about 15.0 wt%, about 10.0 wt% to about 15.0 wt%, about 10.25 wt% to about 15.0 wt%, about 10.5 wt% to about 15.0 wt%, about 10.75 wt% to about 15.0 wt%, about 11.0 wt% to about 15.0 wt%, about 11.25 wt% to about 15.0 wt%, about 11.5 wt% to about 15.0 wt%, about 11.75 wt% to about 15.0 wt%, about 12.0 wt% to about 15.0 wt%, about 12.25 wt% to about 15.0 wt%, about 12.5 wt% to about 15.0 wt%, about 12.75 wt% to about 15.0 wt%, about 13.0 wt% to about 15.0 wt%, about 13.25 wt% to about 15.0 wt%, about 13.5 wt% to about 15.0 wt%, about 13.75 wt% to about 15.0 wt%, about 14.0 wt% to about 15.0 wt%, about 14.25 wt% to about 15.0 wt%, about 14.5 wt% to about 15.0 wt%, or about 14.75 wt% to about 15.0 wt%.
[0095] In some embodiments, the ophthalmic composition comprises ensulizole at a range of 0.25 wt% to 15.0 wt%, 0.5 wt% to 15.0 wt%, 0.75 wt% to 15.0 wt%, 1.0 wt% to 15.0 wt%, 1.25 wt% to 15.0 wt%, 1.5 wt% to 15.0 wt%, 1.75 wt% to 15.0 wt%, 2.0 wt% to 15.0 wt%, 2.25 wt% to 15.0 wt%, 2.5 wt% to 15.0 wt%, 2.75 wt% to 15.0 wt%, 3.0 wt% to 15.0 wt%, 3.25 wt% to 15.0 wt%, 3.5 wt% to 15.0 wt%, 3.75 wt% to 15.0 wt%, 4.0 wt% to 15.0 wt%, 4.25 wt% to 15.0 wt%, 4.5 wt% to 15.0 wt%, 4.75 wt% to 15.0 wt%, 5.0 wt% to 15.0 wt%, 5.25 wt% to 15.0 wt%, 5.5 wt% to 15.0 wt%, 5.75 wt% to 15.0 wt%, 6.0 wt% to 15.0 wt%, 6.25 wt% to 15.0 wt%, 6.5 wt% to 15.0 wt%, 6.75 wt% to 15.0 wt%, 7.0 wt% to 15.0 wt%, 7.25 wt% to 15.0 wt%, 7.5 wt% to 15.0 wt%, 7.75 wt% to 15.0 wt%, 8.0 wt% to 15.0 wt%, 8.25 wt% to 15.0 wt%, 8.5 wt% to 15.0 wt%, 8.75 wt% to 15.0 wt%, 9.0 wt% to 15.0 wt%, 9.25 wt% to 15.0 wt%, 9.5 wt% to 15.0 wt%, 9.75 wt% to 15.0 wt%, 10.0 wt% to 15.0 wt%, 10.25 wt% to 15.0 wt%, 10.5 wt% to 15.0 wt%, 10.75 wt% to 15.0 wt%, 11.0 wt% to 15.0 wt%, 11.25 wt% to 15.0 wt%, 11.5 wt% to 15.0 wt%, 11.75 wt% to 15.0 wt%, 12.0 wt% to 15.0 wt%, 12.25 wt% to 15.0 wt%, 12.5 wt% to 15.0 wt%, 12.75 wt% to 15.0 wt%, 13.0 wt% to 15.0 wt%, 13.25 wt% to 15.0 wt%, 13.5 wt% to 15.0 wt%, 13.75 wt% to 15.0 wt%, 14.0 wt% to 15.0 wt%, 14.25 wt% to 15.0 wt%, 14.5 wt% to 15.0 wt%, or 14.75 wt% to 15.0 wt%.
[0096] In some embodiments, the ophthalmic composition comprises 0.25 wt% ensulizole. In some embodiments, the formulation comprises ensulizole at about 0.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 0.75 wt%. In someAttorney Docket No.56964-703601embodiments, the ophthalmic composition comprises ensulizole at about 1.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 1.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 1.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 1.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 2.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 2.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 2.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 2.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 3.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 3.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 3.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 3.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 4.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 4.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 4.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 4.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 5.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 5.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 5.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 5.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 6.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 6.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 6.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 6.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 7.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 7.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 7.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 7.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 8.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 8.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 8.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 8.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 9.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 9.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 9.50 wt%. In someAttorney Docket No.56964-703601embodiments, the ophthalmic composition comprises ensulizole at about 9.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 10.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 10.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 10.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 10.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 11.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 11.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 11.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 11.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 12.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 12.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 12.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 12.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 13.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 13.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 13.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 13.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 14.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 14.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 14.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 14.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 15.00 wt%.
[0097] In some embodiments, the ophthalmic composition comprises 0.25 wt% ensulizole. In some embodiments, the ophthalmic composition comprises ensulizole at 0.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 0.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 1.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 1.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 1.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 1.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 2.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 2.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 2.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 2.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 3.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 3.25 wt%. In someAttorney Docket No.56964-703601embodiments, the ophthalmic composition comprises ensulizole at 3.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 3.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 4.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 4.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 4.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 4.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 5.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 5.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 5.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 5.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 6.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 6.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 6.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 6.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 7.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 7.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 7.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 7.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 8.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 8.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 8.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 8.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 9.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 9.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 9.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 9.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 10.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 10.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 10.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 10.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 11.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 11.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 11.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 11.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 12.00 wt%. In someAttorney Docket No.56964-703601embodiments, the ophthalmic composition comprises ensulizole at 12.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 12.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 12.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 13.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 13.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 13.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 13.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 14.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 14.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 14.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 14.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 15.00 wt%.
[0098] In some embodiments, the second therapeutic agent is selected from povidone, glycerin, polyethylene glycol 300, polyethylene glycol 400, carboxymethylcellulose, Polysorbate 80, light mineral oil, mineral oil, naphazoline hydrochloride, ketotifen, pheniramine maleate, ketorolac tromethamine, prednisolone acetate, alcaftadine, brimonidine tartrate, timolol maleate, bimatoprost, Brimonidine tartrate, Cyclosporine, Pilocarpine hydrochloride, ketorolac trometamol, antazoline phosphate, fluorometholone, and carmellose sodium, or any combination thereof. In some embodiments, the second therapeutic agent is povidone, glycerin, polyethylene glycol 300, polyethylene glycol 400, carboxymethylcellulose, Polysorbate 80, light mineral oil, mineral oil, naphazoline hydrochloride, ketotifen, pheniramine maleate, ketorolac tromethamine, prednisolone acetate, alcaftadine, brimonidine tartrate, timolol maleate, bimatoprost, Brimonidine tartrate, Cyclosporine, Pilocarpine hydrochloride, ketorolac trometamol, antazoline phosphate, fluorometholone, carmellose sodium, or any combination thereof.
[0099] In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and glycerin. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and propylene glycol. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Soothe® Dry Eye. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Biotrue® Hydration Boost Lubricant Eye Drops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Blink® Triple Care Lubricating Eye Drops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Blink GelTears® Lubricating Eye Drops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Soothe® XP Emollient Eye Drops. In someAttorney Docket No.56964-703601embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Advanced Eye Relief / Redness Instant Relief. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Alaway® Antihistamine Eye Drops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Opcon-A® Allergy Relief Eye Drops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Acuvail®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Pred Forte®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Lastacaft®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Combigan®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Lumigan®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Alphagan®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Refresh® Digital. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Refresh® Relieva® PF Xtra. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and RefreshMega 3®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Refresh Optive®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Resistasis®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Vuity®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Acular®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Albalon®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Albalon A®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and FML Liquifilm® eyedrops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Celluvisc®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Ganafort®.
[0100] In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and glycerin. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and propylene glycol. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Soothe® Dry Eye. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Biotrue® Hydration BoostAttorney Docket No.56964-703601Lubricant Eye Drops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Blink® Triple Care Lubricating Eye Drops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Blink GelTears® Lubricating Eye Drops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Soothe® XP Emollient Eye Drops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Advanced Eye Relief / Redness Instant Relief. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Alaway® Antihistamine Eye Drops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Opcon-A® Allergy Relief Eye Drops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Acuvail®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Pred Forte®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Lastacaft®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Combigan®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Lumigan®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Alphagan®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Refresh® Digital. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Refresh® Relieva® PF Xtra. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and RefreshMega 3®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Refresh Optive®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Resistasis®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Vuity®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Acular®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Albalon®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Albalon A®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and FML Liquifilm® eyedrops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Celluvisc®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Ganafort®.
[0101] Ophthalmic Sunscreen Compositions
[0102] In some embodiments, the ophthalmic sunscreen compositions described herein comprise about 0.25 wt% to about 15.0 wt% of ensulizole and a second agent.Attorney Docket No.56964-703601
[0103] In some embodiments, the ophthalmic sunscreen composition comprises 0.25 wt% comprises ensulizole at a range of about 0.25 wt% to about 15.0 wt%, about 0.5 wt% to about 15.0 wt%, about 0.75 wt% to about 15.0 wt%, about 1.0 wt% to about 15.0 wt%, about 1.25 wt% to about 15.0 wt%, about 1.5 wt% to about 15.0 wt%, about 1.75 wt% to about 15.0 wt%, about 2.0 wt% to about 15.0 wt%, about 2.25 wt% to about 15.0 wt%, about 2.5 wt% to about 15.0 wt%, about 2.75 wt% to about 15.0 wt%, about 3.0 wt% to about 15.0 wt%, about 3.25 wt% to about 15.0 wt%, about 3.5 wt% to about 15.0 wt%, about 3.75 wt% to about 15.0 wt%, about 4.0 wt% to about 15.0 wt%, about 4.25 wt% to about 15.0 wt%, about 4.5 wt% to about 15.0 wt%, about 4.75 wt% to about 15.0 wt%, about 5.0 wt% to about 15.0 wt%, about 5.25 wt% to about 15.0 wt%, about 5.5 wt% to about 15.0 wt%, about 5.75 wt% to about 15.0 wt%, about 6.0 wt% to about 15.0 wt%, about 6.25 wt% to about 15.0 wt%, about 6.5 wt% to about 15.0 wt%, about 6.75 wt% to about 15.0 wt%, about 7.0 wt% to about 15.0 wt%, about 7.25 wt% to about 15.0 wt%, about 7.5 wt% to about 15.0 wt%, about 7.75 wt% to about 15.0 wt%, about 8.0 wt% to about 15.0 wt%, about 8.25 wt% to about 15.0 wt%, about 8.5 wt% to about 15.0 wt%, about 8.75 wt% to about 15.0 wt%, about 9.0 wt% to about 15.0 wt%, about 9.25 wt% to about 15.0 wt%, about 9.5 wt% to about 15.0 wt%, about 9.75 wt% to about 15.0 wt%, about 10.0 wt% to about 15.0 wt%, about 10.25 wt% to about 15.0 wt%, about 10.5 wt% to about 15.0 wt%, about 10.75 wt% to about 15.0 wt%, about 11.0 wt% to about 15.0 wt%, about 11.25 wt% to about 15.0 wt%, about 11.5 wt% to about 15.0 wt%, about 11.75 wt% to about 15.0 wt%, about 12.0 wt% to about 15.0 wt%, about 12.25 wt% to about 15.0 wt%, about 12.5 wt% to about 15.0 wt%, about 12.75 wt% to about 15.0 wt%, about 13.0 wt% to about 15.0 wt%, about 13.25 wt% to about 15.0 wt%, about 13.5 wt% to about 15.0 wt%, about 13.75 wt% to about 15.0 wt%, about 14.0 wt% to about 15.0 wt%, about 14.25 wt% to about 15.0 wt%, about 14.5 wt% to about 15.0 wt%, or about 14.75 wt% to about 15.0 wt%.
[0104] In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at a range of 0.25 wt% to 15.0 wt%, 0.5 wt% to 15.0 wt%, 0.75 wt% to 15.0 wt%, 1.0 wt% to 15.0 wt%, 1.25 wt% to 15.0 wt%, 1.5 wt% to 15.0 wt%, 1.75 wt% to 15.0 wt%, 2.0 wt% to 15.0 wt%, 2.25 wt% to 15.0 wt%, 2.5 wt% to 15.0 wt%, 2.75 wt% to 15.0 wt%, 3.0 wt% to 15.0 wt%, 3.25 wt% to 15.0 wt%, 3.5 wt% to 15.0 wt%, 3.75 wt% to 15.0 wt%, 4.0 wt% to 15.0 wt%, 4.25 wt% to 15.0 wt%, 4.5 wt% to 15.0 wt%, 4.75 wt% to 15.0 wt%, 5.0 wt% to 15.0 wt%, 5.25 wt% to 15.0 wt%, 5.5 wt% to 15.0 wt%, 5.75 wt% to 15.0 wt%, 6.0 wt% to 15.0 wt%, 6.25 wt% to 15.0 wt%, 6.5 wt% to 15.0 wt%, 6.75 wt% to 15.0 wt%, 7.0 wt% to 15.0 wt%, 7.25 wt% to 15.0 wt%, 7.5 wt% to 15.0 wt%, 7.75 wt% to 15.0 wt%, 8.0 wt% to 15.0 wt%, 8.25 wt% to 15.0 wt%, 8.5 wt% to 15.0 wt%, 8.75 wt% to 15.0 wt%, 9.0 wt% to 15.0 wt%, 9.25 wt% to 15.0 wt%, 9.5 wt% to 15.0 wt%, 9.75 wt% to 15.0 wt%, 10.0 wt% to 15.0 wt%, 10.25 wt% to 15.0 wt%, 10.5 wt% toAttorney Docket No.56964-70360115.0 wt%, 10.75 wt% to 15.0 wt%, 11.0 wt% to 15.0 wt%, 11.25 wt% to 15.0 wt%, 11.5 wt% to 15.0 wt%, 11.75 wt% to 15.0 wt%, 12.0 wt% to 15.0 wt%, 12.25 wt% to 15.0 wt%, 12.5 wt% to 15.0 wt%, 12.75 wt% to 15.0 wt%, 13.0 wt% to 15.0 wt%, 13.25 wt% to 15.0 wt%, 13.5 wt% to 15.0 wt%, 13.75 wt% to 15.0 wt%, 14.0 wt% to 15.0 wt%, 14.25 wt% to 15.0 wt%, 14.5 wt% to 15.0 wt%, or 14.75 wt% to 15.0 wt%.
[0105] In some embodiments, the ophthalmic sunscreen compositions comprise 0.25 wt% ensulizole. In some embodiments, the formulation comprises ensulizole at about 0.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 0.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 1.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 1.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 1.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 1.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 2.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 2.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 2.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 2.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 3.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 3.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 3.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 3.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 4.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 4.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 4.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 4.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 5.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 5.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 5.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 5.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 6.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 6.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 6.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 6.75 wt%. In some embodiments, theAttorney Docket No.56964-703601ophthalmic sunscreen composition comprises ensulizole at about 7.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 7.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 7.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 7.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 8.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 8.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 8.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 8.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 9.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 9.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 9.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 9.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 10.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 10.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 10.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 10.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 11.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 11.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 11.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 11.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 12.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 12.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 12.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 12.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 13.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 13.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 13.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 13.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 14.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 14.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 14.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprisesAttorney Docket No.56964-703601ensulizole at about 14.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at about 15.00 wt%.
[0106] In some embodiments, the ophthalmic sunscreen composition comprises 0.25 wt% ensulizole. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 0.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 0.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 1.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 1.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 1.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 1.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 2.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 2.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 2.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 2.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 3.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 3.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 3.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 3.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 4.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 4.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 4.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 4.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 5.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 5.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 5.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 5.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 6.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 6.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 6.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 6.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 7.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 7.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 7.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 7.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 8.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole atAttorney Docket No.56964-7036018.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 8.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 8.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 9.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 9.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 9.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 9.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 10.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 10.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 10.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 10.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 11.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 11.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 11.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 11.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 12.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 12.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 12.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 12.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 13.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 13.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 13.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 13.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 14.00 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 14.25 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 14.50 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 14.75 wt%. In some embodiments, the ophthalmic sunscreen composition comprises ensulizole at 15.00 wt%.
[0107] In some embodiments, the second therapeutic agent is selected from povidone, glycerin, polyethylene glycol 300, polyethylene glycol 400, carboxymethylcellulose, Polysorbate 80, light mineral oil, mineral oil, naphazoline hydrochloride, ketotifen, pheniramine maleate, ketorolac tromethamine, prednisolone acetate, alcaftadine, brimonidine tartrate, timolol maleate, bimatoprost, Brimonidine tartrate, Cyclosporine, Pilocarpine hydrochloride, ketorolac trometamol, antazoline phosphate, fluorometholone, and carmellose sodium, or any combination thereof. In some embodiments, the second therapeutic agent is povidone, glycerin, polyethyleneAttorney Docket No.56964-703601glycol 300, polyethylene glycol 400, carboxymethylcellulose, Polysorbate 80, light mineral oil, mineral oil, naphazoline hydrochloride, ketotifen, pheniramine maleate, ketorolac tromethamine, prednisolone acetate, alcaftadine, brimonidine tartrate, timolol maleate, bimatoprost, Brimonidine tartrate, Cyclosporine, Pilocarpine hydrochloride, ketorolac trometamol, antazoline phosphate, fluoromethoIone, carmellose sodium, or any combination thereof.
[0108] In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and glycerin. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and propylene glycol. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Soothe® Dry Eye. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Biotrue® Hydration Boost Lubricant Eye Drops. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Blink® Triple Care Lubricating Eye Drops. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Blink GelTears® Lubricating Eye Drops. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Soothe® XP Emollient Eye Drops. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Advanced Eye Relief / Redness Instant Relief. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Alaway® Antihistamine Eye Drops. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Opcon-A® Allergy Relief Eye Drops. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Acuvail®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Pred Forte®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Lastacaft®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Combigan®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Lumigan®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Alphagan®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Refresh® Digital. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Refresh® Relieva® PF Xtra. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and RefreshMega 3®. InAttorney Docket No.56964-703601some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Refresh Optive®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Resistasis®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Vuity®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Acular®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Albalon®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Albalon A®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and FML Liquifilm® eyedrops. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Celluvisc®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Ganafort®.
[0109] In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and glycerin. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and propylene glycol. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and Soothe® Dry Eye. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and Biotrue® Hydration Boost Lubricant Eye Drops. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and Blink® Triple Care Lubricating Eye Drops. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and Blink GelTears® Lubricating Eye Drops. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and Soothe® XP Emollient Eye Drops. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and Advanced Eye Relief / Redness Instant Relief. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and Alaway® Antihistamine Eye Drops. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and Opcon-A® Allergy Relief Eye Drops. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and Acuvail®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and Pred Forte®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and Lastacaft®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and Combigan®. In some embodiments, the ophthalmic sunscreen composition comprises aboutAttorney Docket No.56964-7036010.25 wt% of ensulizole and Lumigan®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and Alphagan®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and Refresh® Digital. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and Refresh® Relieva® PF Xtra. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and RefreshMega 3®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and Refresh Optive®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and Resistasis®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and Vuity®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and Acular®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and Albalon®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and Albalon A®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and FML Liquifilm® eyedrops. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and Celluvisc®. In some embodiments, the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole and Ganafort®.
[0110] METHODS[oni] Provided herein are methods of ocular UV protection. In some embodiments, the compositions, formulations, ophthalmic compositions, or ophthalmic sunscreen compositions described here may be used for methods of ocular UV protection.
[0112] In an aspect, described herein are methods of ocular UV protection comprising applying the compositions, formulations, ophthalmic compositions, or ophthalmic sunscreen compositions described herein, to an eye. In an aspect, described herein are methods of ocular UV protection comprising applying an ophthalmic composition to an eye, wherein the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole. In an aspect, described herein are methods of ocular UV protection comprising applying an ophthalmic composition to an eye, wherein the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole; and a second therapeutic agent.
[0113] In some embodiments, the methods of ocular UV protection comprise applying an ophthalmic composition to an eye, wherein the ophthalmic composition comprises ensulizole at a range of about 0.25 wt% to about 15 wt%. In some embodiments, the methods of ocular UV comprise applying an ophthalmic composition to an eye, wherein the ophthalmic composition comprises ensulizole at a range of about 0.25 wt% to about 15.0 wt%, about 0.5 wt% to aboutAttorney Docket No.56964-70360115.0 wt%, about 0.75 wt% to about 15.0 wt%, about 1.0 wt% to about 15.0 wt%, about 1.25 wt% to about 15.0 wt%, about 1.5 wt% to about 15.0 wt%, about 1.75 wt% to about 15.0 wt%, about 2.0 wt% to about 15.0 wt%, about 2.25 wt% to about 15.0 wt%, about 2.5 wt% to about 15.0 wt%, about 2.75 wt% to about 15.0 wt%, about 3.0 wt% to about 15.0 wt%, about 3.25 wt% to about 15.0 wt%, about 3.5 wt% to about 15.0 wt%, about 3.75 wt% to about 15.0 wt%, about 4.0 wt% to about 15.0 wt%, about 4.25 wt% to about 15.0 wt%, about 4.5 wt% to about 15.0 wt%, about 4.75 wt% to about 15.0 wt%, about 5.0 wt% to about 15.0 wt%, about 5.25 wt% to about 15.0 wt%, about 5.5 wt% to about 15.0 wt%, about 5.75 wt% to about 15.0 wt%, about 6.0 wt% to about 15.0 wt%, about 6.25 wt% to about 15.0 wt%, about 6.5 wt% to about 15.0 wt%, about 6.75 wt% to about 15.0 wt%, about 7.0 wt% to about 15.0 wt%, about 7.25 wt% to about 15.0 wt%, about 7.5 wt% to about 15.0 wt%, about 7.75 wt% to about 15.0 wt%, about 8.0 wt% to about 15.0 wt%, about 8.25 wt% to about 15.0 wt%, about 8.5 wt% to about 15.0 wt%, about 8.75 wt% to about 15.0 wt%, about 9.0 wt% to about 15.0 wt%, about 9.25 wt% to about 15.0 wt%, about 9.5 wt% to about 15.0 wt%, about 9.75 wt% to about 15.0 wt%, about 10.0 wt% to about 15.0 wt%, about 10.25 wt% to about 15.0 wt%, about 10.5 wt% to about 15.0 wt%, about 10.75 wt% to about 15.0 wt%, about 11.0 wt% to about 15.0 wt%, about 11.25 wt% to about 15.0 wt%, about 11.5 wt% to about 15.0 wt%, about 11.75 wt% to about 15.0 wt%, about 12.0 wt% to about 15.0 wt%, about 12.25 wt% to about 15.0 wt%, about 12.5 wt% to about 15.0 wt%, about 12.75 wt% to about 15.0 wt%, about 13.0 wt% to about 15.0 wt%, about 13.25 wt% to about 15.0 wt%, about 13.5 wt% to about 15.0 wt%, about 13.75 wt% to about 15.0 wt%, about 14.0 wt% to about 15.0 wt%, about 14.25 wt% to about 15.0 wt%, about 14.5 wt% to about 15.0 wt%, or about 14.75 wt% to about 15.0 wt%.
[0114] In some embodiments, the methods of ocular UV protection comprise applying an ophthalmic composition to an eye, wherein the ophthalmic composition comprises ensulizole at a range of 0.25 wt% to 15.0 wt%, 0.5 wt% to 15.0 wt%, 0.75 wt% to 15.0 wt%, 1.0 wt% to 15.0 wt%, 1.25 wt% to 15.0 wt%, 1.5 wt% to 15.0 wt%, 1.75 wt% to 15.0 wt%, 2.0 wt% to 15.0 wt%, 2.25 wt% to 15.0 wt%, 2.5 wt% to 15.0 wt%, 2.75 wt% to 15.0 wt%, 3.0 wt% to 15.0 wt%, 3.25 wt% to 15.0 wt%, 3.5 wt% to 15.0 wt%, 3.75 wt% to 15.0 wt%, 4.0 wt% to 15.0 wt%, 4.25 wt% to 15.0 wt%, 4.5 wt% to 15.0 wt%, 4.75 wt% to 15.0 wt%, 5.0 wt% to 15.0 wt%, 5.25 wt% to 15.0 wt%, 5.5 wt% to 15.0 wt%, 5.75 wt% to 15.0 wt%, 6.0 wt% to 15.0 wt%, 6.25 wt% to 15.0 wt%, 6.5 wt% to 15.0 wt%, 6.75 wt% to 15.0 wt%, 7.0 wt% to 15.0 wt%, 7.25 wt% to 15.0 wt%, 7.5 wt% to 15.0 wt%, 7.75 wt% to 15.0 wt%, 8.0 wt% to 15.0 wt%, 8.25 wt% to 15.0 wt%, 8.5 wt% to 15.0 wt%, 8.75 wt% to 15.0 wt%, 9.0 wt% to 15.0 wt%, 9.25 wt% to 15.0 wt%, 9.5 wt% to 15.0 wt%, 9.75 wt% to 15.0 wt%, 10.0 wt% to 15.0 wt%, 10.25 wt% to 15.0 wt%, 10.5 wt% to 15.0 wt%, 10.75 wt% to 15.0 wt%, 11.0 wt% to 15.0 wt%, 11.25 wt% to 15.0 wt%, 11.5 wt% toAttorney Docket No.56964-70360115.0 wt%, 11.75 wt% to 15.0 wt%, 12.0 wt% to 15.0 wt%, 12.25 wt% to 15.0 wt%, 12.5 wt% to 15.0 wt%, 12.75 wt% to 15.0 wt%, 13.0 wt% to 15.0 wt%, 13.25 wt% to 15.0 wt%, 13.5 wt% to 15.0 wt%, 13.75 wt% to 15.0 wt%, 14.0 wt% to 15.0 wt%, 14.25 wt% to 15.0 wt%, 14.5 wt% to 15.0 wt%, or 14.75 wt% to 15.0 wt%.
[0115] In some embodiments, the ophthalmic composition comprises 0.25 wt% ensulizole. In some embodiments, the formulation comprises ensulizole at about 0.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 0.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 1.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 1.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 1.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 1.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 2.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 2.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 2.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 2.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 3.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 3.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 3.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 3.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 4.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 4.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 4.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 4.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 5.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 5.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 5.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 5.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 6.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 6.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 6.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 6.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 7.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 7.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 7.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 7.75 wt%. In someAttorney Docket No.56964-703601embodiments, the ophthalmic composition comprises ensulizole at 8.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 8.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 8.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 8.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 9.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 9.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 9.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 9.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 10.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 10.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 10.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 10.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 11.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 11.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 11.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 11.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 12.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 12.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 12.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 12.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 13.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 13.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 13.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 13.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 14.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 14.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 14.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 14.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at about 15.00 wt%.
[0116] In some embodiments, the ophthalmic composition comprises 0.25 wt% ensulizole. In some embodiments, the ophthalmic composition comprises ensulizole at 0.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 0.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 1.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 1.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 1.50 wt%. In someAttorney Docket No.56964-703601embodiments, the ophthalmic composition comprises ensulizole at 1.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 2.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 2.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 2.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 2.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 3.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 3.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 3.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 3.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 4.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 4.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 4.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 4.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 5.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 5.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 5.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 5.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 6.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 6.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 6.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 6.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 7.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 7.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 7.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 7.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 8.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 8.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 8.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 8.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 9.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 9.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 9.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 9.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 10.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 10.25 wt%. In someAttorney Docket No.56964-703601embodiments, the ophthalmic composition comprises ensulizole at 10.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 10.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 11.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 11.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 11.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 11.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 12.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 12.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 12.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 12.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 13.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 13.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 13.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 13.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 14.00 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 14.25 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 14.50 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 14.75 wt%. In some embodiments, the ophthalmic composition comprises ensulizole at 15.00 wt%.
[0117] In some embodiments, the methods of ocular UV protection comprise applying an ophthalmic composition to an eye, wherein the ophthalmic composition comprises a second therapeutic agent. In some embodiments, the second therapeutic agent comprises salicylic acid (“2-Hydroxybenzoic acid”, “2-Carboxyphenol”, C7H6O3, CAS #:69-72-7), niacinamide (“Nicotinamide”, “3-pyridinecarboxamide niacinamide”, C6H6N2O, CAS#:98-92-0), commercially available eyedrop formulations comprising one or more active ingredients, or one or more active ingredients contained in commercially available eyedrop formulations. In some embodiments, the second therapeutic agent comprises salicylic acid. In some embodiments, the second therapeutic agent comprises niacinamide. In some embodiments, the second therapeutic agent comprises commercially available eyedrop formulations comprising one or more active ingredients. In some embodiments, the second therapeutic agent comprises the one or more active ingredients contained in commercially available eyedrop formulations.
[0118] In some embodiments, the second therapeutic agent is selected from povidone, glycerin, polyethylene glycol 300, polyethylene glycol 400, carboxymethylcellulose, Polysorbate 80, light mineral oil, mineral oil, naphazoline hydrochloride, ketotifen, pheniramine maleate, ketorolac tromethamine, prednisolone acetate, alcaftadine, brimonidine tartrate, timolol maleate,Attorney Docket No.56964-703601bimatoprost, Brimonidine tartrate, Cyclosporine, Pilocarpine hydrochloride, ketorolac trometamol, antazoline phosphate, fluoromethoIone, and carmellose sodium, or any combination thereof. In some embodiments, the second therapeutic agent is povidone, glycerin, polyethylene glycol 300, polyethylene glycol 400, carboxymethylcellulose, Polysorbate 80, light mineral oil, mineral oil, naphazoline hydrochloride, ketotifen, pheniramine maleate, ketorolac tromethamine, prednisolone acetate, alcaftadine, brimonidine tartrate, timolol maleate, bimatoprost, Brimonidine tartrate, Cyclosporine, Pilocarpine hydrochloride, ketorolac trometamol, antazoline phosphate, fluoromethoIone, carmellose sodium, or any combination thereof.
[0119] In some embodiments, the second therapeutic agent comprises the commercially available eyedrop formulations comprising one or more active ingredients. Non-limiting examples of commercially available eyedrop formulations comprising one or more active ingredients include: Soothe® Dry Eye [Active ingredient: Povidone (1.25%)]; Biotrue® Hydration Boost Lubricant Eye Drops [Active ingredient: Glycerin (0.5%)]; Blink® Triple Care Lubricating Eye Drops [Active ingredient: Polyethylene Glycol 400 (0.25%)]; Blink GelTears® Lubricating Eye Drops [Active ingredient: Polyethylene Glycol 400 (0.25%)]; Soothe® XP Emollient Eye Drops [Active ingredients: Light mineral oil (1.0%), Mineral oil (4.5%)];Advanced Eye Relief / Redness Instant Relief [Active ingredients: Naphazoline hydrochloride (0.012%) and Polyethylene glycol 300 (0.2%)]; Alaway® Antihistamine Eye Drops [Active ingredient: Ketotifen (0.025%)]; Opcon-A® Allergy Relief Eye Drops [Active ingredients: Naphazoline HC1 (0.02675%), Pheniramine Maleate (0.135%)]; Acuvail® [Active ingredient: Ketorolac tromethamine (0.45%)]; Pred Forte® [Active ingredient: Prednisolone acetate (microfine suspension) (1%)]; Lastacaft® [Active ingredient: Alcaftadine (0.25%)]; Combigan® [Active ingredients: Brimonidine tartrate / Timolol maleate ophthalmic solution (0.2% / 0.5%)]; Lumigan® [Active ingredient: Bimatoprost (0.01%)]; Alphagan® [Active ingredients:Brimonidine tartrate 0.1% (1 mg / mL) or 0.15% (1.5 mg / mL)]; Refresh® Digital [Active ingredients: Carboxymethylcellulose (CMC) (0.5%), Glycerin (1%), Polysorbate 80 (0.5%); Refresh® Relieva® PF Xtra [Active ingredients: Carboxymethylcellulose (CMC) (0.5%), Glycerin (0.9%)]; Refresh Mega 3® [Active ingredients: Carboxymethylcellulose (CMC) (0.5%), Glycerin (1%), Polysorbate 80 (0.5%); Refresh Optive® [Active ingredients:Carboxymethylcellulose (CMC) (1%), Glycerin (0.9%)]; Resistasis® [Active ingredient:Cyclosporine (0.5%)]; Vuity® [Active ingredient: Pilocarpine hydrochloride (1.25%)]; Acular® [Active ingredient: Ketorolac trometamol (5%)]; Albalon® [Active ingredient: Naphazoline hydrochloride]; Albalon A® [Active ingredients: Naphazoline hydrochloride (0.05%), Antazoline phosphate (0.5%)]; FML Liquifilm® [Active ingredient: FluoromethoIone (1.0%)];Attorney Docket No.56964-703601Celluvisc® [Active ingredient: Carmellose sodium (0.5% / 1.0%)]; or Ganafort® [Active ingredients: Bimatoprost and Timolol (0.3 mg / mL / 0.5 mg / mL)].
[0120] In some embodiments, the second therapeutic agent comprises Soothe® Dry Eye, Biotrue® Hydration Boost Lubricant Eye Drops, Blink® Triple Care Lubricating Eye Drops, Blink GelTears® Lubricating Eye Drops, Soothe® XP Emollient Eye Drops, Advanced Eye Relief / Redness Instant Relief, Alaway® Antihistamine Eye Drops, Opcon-A® Allergy Relief Eye Drops, Acuvail®, Pred Forte®, Lastacaft®, Combigan®, Lumigan®, Alphagan®, Refresh® Digital, Refresh® Relieva® PF Xtra, RefreshMega 3®, Refresh Optive ®, Resistasis®, Vuity®, Acular®, Albalon®, Albalon A®, FML Liquifilm® eyedrops, Celluvisc®, or Ganafort®.
[0121] In some embodiments, the second therapeutic agent comprises Soothe® Dry Eye. In some embodiments, the second therapeutic agent comprises Biotrue® Hydration Boost Lubricant Eye Drops. In some embodiments, the second therapeutic agent comprises Blink® Triple Care Lubricating Eye Drops. In some embodiments, the second therapeutic agent comprises Blink GelTears® Lubricating Eye Drops. In some embodiments, the second therapeutic agent comprises Soothe® XP Emollient Eye Drops. In some embodiments, the second therapeutic agent comprises Advanced Eye Relief / Redness Instant Relief. In some embodiments, the second therapeutic agent comprises Alaway® Antihistamine Eye Drops. In some embodiments, the second therapeutic agent comprises Opcon-A® Allergy Relief Eye Drops. In some embodiments, the second therapeutic agent comprises Acuvail®. In some embodiments, the second therapeutic agent comprises Pred Forte®. In some embodiments, the second therapeutic agent comprises Lastacaft®. In some embodiments, the second therapeutic agent comprises Combigan®. In some embodiments, the second therapeutic agent comprises Lumigan®. In some embodiments, the second therapeutic agent comprises Alphagan®. In some embodiments, the second therapeutic agent comprises Refresh® Digital. In some embodiments, the second therapeutic agent comprises Refresh® Relieva® PF Xtra. In some embodiments, the second therapeutic agent comprises RefreshMega 3®. In some embodiments, the second therapeutic agent comprises Refresh Optive®. In some embodiments, the second therapeutic agent comprises Resistasis®. In some embodiments, the second therapeutic agent comprises Vuity®. In some embodiments, the second therapeutic agent comprises Acular®. In some embodiments, the second therapeutic agent comprises Albalon®. In some embodiments, the second therapeutic agent comprises Albalon A®. In some embodiments, the second therapeutic agent comprises FML Liquifilm® eyedrops. In some embodiments, the second therapeutic agent comprises Celluvisc®. In some embodiments, the second therapeutic agent comprises Ganafort®.
[0122] In some embodiments, the second therapeutic agent comprises the one or more active ingredients contained in the commercially available eyedrop formulations. In some embodiments,Attorney Docket No.56964-703601the second therapeutic agent is selected from the group consisting of: povidone, glycerin, polyethylene glycol 400, light mineral oil, mineral oil, naphazoline hydrochloride, polyethylene glycol 300, ketotifen, pheniramine maleate, ketorolac tromethamine, prednisolone acetate, alcaftadine, brimonidine tartrate, timolol maleate, bimatoprost, carboxymethylcellulose (CMC), polysorbate 80, cyclosporine, pilocarpine hydrochloride, antazoline phosphate, fluoromethoIone, carmellose sodium, and timolol.
[0123] In some embodiments, the second therapeutic agent comprises the one or more active ingredients contained in the commercially available eyedrop formulations. In some embodiments, the second therapeutic agent comprises povidone, glycerin, polyethylene glycol 400, light mineral oil, mineral oil, naphazoline hydrochloride, polyethylene glycol 300, ketotifen, pheniramine maleate, ketorolac tromethamine, prednisolone acetate, alcaftadine, brimonidine tartrate, timolol maleate, bimatoprost, carboxymethylcellulose (CMC), polysorbate 80, cyclosporine, pilocarpine hydrochloride, antazoline phosphate, fluorometholone, carmellose sodium, or timolol. In some embodiments, the second therapeutic agent comprises povidone. In some embodiments, the second therapeutic agent comprises glycerin. In some embodiments, the second therapeutic agent comprises polyethylene glycol 400. In some embodiments, the second therapeutic agent comprises light mineral oil. In some embodiments, the second therapeutic agent comprises mineral oil. In some embodiments, the second therapeutic agent comprises naphazoline hydrochloride. In some embodiments, the second therapeutic agent comprises polyethylene glycol 300. In some embodiments, the second therapeutic agent comprises ketotifen. In some embodiments, the second therapeutic agent comprises pheniramine maleate. In some embodiments, the second therapeutic agent comprises ketorolac tromethamine. In some embodiments, the second therapeutic agent comprises prednisolone acetate. In some embodiments, the second therapeutic agent comprises alcaftadine. In some embodiments, the second therapeutic agent comprises brimonidine tartrate. In some embodiments, the second therapeutic agent comprises timolol maleate. In some embodiments, the second therapeutic agent comprises bimatoprost. In some embodiments, the second therapeutic agent comprises carboxymethylcellulose (CMC). In some embodiments, the second therapeutic agent comprises polysorbate 80. In some embodiments, the second therapeutic agent comprises cyclosporine. In some embodiments, the second therapeutic agent comprises pilocarpine hydrochloride. In some embodiments, the second therapeutic agent comprises antazoline phosphate. In some embodiments, the second therapeutic agent comprises fluorometholone. In some embodiments, the second therapeutic agent comprises carmellose sodium. In some embodiments, the second therapeutic agent comprises timolol.Attorney Docket No.56964-703601
[0124] In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and glycerin. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and propylene glycol. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Soothe® Dry Eye. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Biotrue® Hydration Boost Lubricant Eye Drops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Blink® Triple Care Lubricating Eye Drops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Blink GelTears® Lubricating Eye Drops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Soothe® XP Emollient Eye Drops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Advanced Eye Relief / Redness Instant Relief. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Alaway® Antihistamine Eye Drops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Opcon-A® Allergy Relief Eye Drops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Acuvail®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Pred Forte®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Lastacaft®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Combigan®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Lumigan®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Alphagan®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Refresh® Digital. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Refresh® Relieva® PF Xtra. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and RefreshMega 3®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Refresh Optive®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Resistasis®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Vuity®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Acular®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole andAttorney Docket No.56964-703601Albalon®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Albalon A®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and FML Liquifilm® eyedrops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Celluvisc®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and Ganafort®.
[0125] In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and glycerin. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and propylene glycol. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Soothe® Dry Eye. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Biotrue® Hydration Boost Lubricant Eye Drops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Blink® Triple Care Lubricating Eye Drops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Blink GelTears® Lubricating Eye Drops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Soothe® XP Emollient Eye Drops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Advanced Eye Relief / Redness Instant Relief. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Alaway® Antihistamine Eye Drops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Opcon-A® Allergy Relief Eye Drops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Acuvail®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Pred Forte®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Lastacaft®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Combigan®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Lumigan®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Alphagan®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Refresh® Digital. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Refresh® Relieva® PF Xtra. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and RefreshMega 3®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Refresh Optive®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Resistasis®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Vuity®. In some embodiments, the ophthalmic compositionAttorney Docket No.56964-703601comprises about 0.25 wt% of ensulizole and Acular®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Albalon®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Albalon A®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and FML Liquifilm® eyedrops. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Celluvisc®. In some embodiments, the ophthalmic composition comprises about 0.25 wt% of ensulizole and Ganafort®.
[0126] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. It is not intended that the invention be limited by the specific examples provided within the specification. While the invention has been described with reference to the aforementioned specification, the descriptions and illustrations of the embodiments herein are not meant to be construed in a limiting sense. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. Furthermore, it shall be understood that all aspects of the invention are not limited to the specific depictions, configurations or relative proportions set forth herein which depend upon a variety of conditions and variables. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is therefore contemplated that the invention shall also cover any such alternatives, modifications, variations, or equivalents. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.EXAMPLES
[0127] The application may be better understood by reference to the following non-limiting examples, which are provided as exemplary embodiments of the application. The following examples are presented in order to more fully illustrate embodiments and should in no way be construed, however, as limiting the broad scope of the application.
[0128] Example 1: UVB Absorbance of 0.25 wt% Ensulizole Eyedrops vs Commercially Available Eyedrops
[0129] The UVB absorbance properties of 0.25% ensulizole eyedrop formulations were first showcased in vitro as comparison studies vs three commercially available eyedrops, the results of which are summarized in Table 1.
[0130] Equipment
[0131] SILVER-Nova Compact research grade spectrometer for > 190-11 lOnm range, TE cooled 2048 element CCD detector with enhanced UV coating & detector lens assembly forAttorney Docket No. 56964-703601extreme sensitivity, 600g / mm dual blaze grating for super range efficiency, integrated order sorting filters, slit-25, USB-2 interface cable, +5v adapter.
[0132] Preconfigured Dual UV-VIS lamp setup includes the high power SL3 Deuterium lamp with installed DCX amplification lens and Filter-U330 for deuterium spike removal; Vertical transmission fixture with variable path length, includes 2 collimating lenses; 4-way fiber optic cuvette holder.
[0133] FireflySci Type 42- 0.2 mm demountable disc-shaped circular dichroism quartz cuvettes, close top; light path 0.2 mm; outer diameter 22 mm; inner diameter 16 mm; capacity 0.04 ml.
[0134] Procedure
[0135] UVB Absorbance spectra of the undiluted eyedrops (containing ensulizole or commercial alternatives) were recorded in Type 42 (path length 0.2 mm) disc-shaped circular quartz cuvettes vs. distilled water as a reference (A=0). Integration time 60 milliseconds; average of 5 measurements; temperature compensation “on”.
[0136] For measuring performance of eye drops in identical reasonable conditions, a liquid layer of appropriate thickness was made by a single eye drop instillation spread over area comparable to an exposed human eye-ball surface. Typical ophthalmic solutions available for administration in a wide variety of glass and plastic dropper bottles which deliver drops with a volume between 25 and 70 microliters (0.025-0.07 ml). Thus, 40 microliter (0.04 ml) was seen as a reasonable volume for a single eye drop instillation. For both men and women, the mean surface area of eyeball exposed to external factors in the working environment is about 1.72 -1.82 cm2. Thus, 2 cm2 was seen as a reasonable area to mimic that of an exposed human eyeball.
[0137] UVB absorbance was calculated using the following equation:Standard AM 1> S Seiar Irradiancs,W * m"* » »m*’ ) * ( o100% * [1 - ylSallLtf Standard AM . i. S Sotar frradtance,i W » m * nns "1] j
[0138] Eyedrop formulations containing 0.25 wt% ensulizole were first compared to commercially available Refresh Optive® Advanced Lubricant Eye Drops (Fig. 4A). Absorbance data and calculations according to the equation above indicate that 0.25%wt formulations block -96% of UVB (290-320 nm) sunlight, while Refresh Optive® Advanced Lubricant Eye Drops block -16% of UVB sunlight. 0.25 wt% ensulizole formulations were ~6x more effective at blocking UVB compared to Refresh Optive® (Table 1).
[0139] Next, eyedrop formulations containing 0.25 wt% ensulizole were compared to commercially available Drop Defence® Anti UV eyedrops (Fig. 4B). Absorbance data andAttorney Docket No.56964-703601calculations according to the equation above indicate that 0.25 wt% ensulizole formulations block -96% of UVB (290-320 nm) sunlight, while Drop Defence® blocks -11% of UVB (290-320 nm) sunlight. 0.25 wt% ensulizole formulations were ~8.72x more effective at blocking UVB than Drop Defence® (Table 1).
[0140] Last, eyedrop formulations containing 0.25 wt% ensulizole were compared to commercially available Rohto® Dual Light Relief eyedrops (Fig. 4C). Absorbance data and calculations according to the equation above indicate that 0.25 wt% ensulizole formulations block -96% of UVB (290-320 nm) sunlight, while Rohto® Dual Light Relief blocks -3% of UVB (290-320 nm) sunlight. 0.25 wt% ensulizole formulations were ~32x more effective at blocking UVB than Rohto® Dual Light Relief (Table 1).
[0141] Table 1: UVB absorbance of Exemplified EyedropsEyedrops UVB AbsorptionRefresh Optive® 16%Drop Defence® 11%Rohto® 3%0.25 wt% Ensulizole Eyedrops 96%
[0142] Example 2: Human Ocular Tolerability Study
[0143] In certain embodiments, the ophthalmic ultraviolet-protective compositions described herein may demonstrate excellent ocular biocompatibility and ophthalmic tolerability following repeated topical ocular administration.
[0144] In certain embodiments, ophthalmic formulations comprising approximately 0.25 wt% phenylbenzimidazole sulfonic acid (ensulizole; PBSA) can be administered to human subjects in an IRB-approved prospective ocular tolerability evaluation.
[0145] In certain embodiments, six human subjects can receive repeated topical ocular administration of a sterile GMP-grade ophthalmic ultraviolet-protective formulation comprising approximately 0.25 wt% ensulizole.
[0146] In certain embodiments, the ophthalmic formulation may be administered approximately four times daily for approximately fourteen consecutive days.
[0147] In certain embodiments, repeated administration may demonstrate excellent ocular tolerability with no clinically significant ocular irritation, no clinically significant allergic reactions, no discontinuations related to adverse events, no clinically significant ocular surfaceAttorney Docket No.56964-703601toxicity, no clinically significant conjunctival injury, no clinically significant corneal injury, or combinations thereof.
[0148] In certain embodiments, repeated ophthalmic administration may demonstrate preservation of ocular comfort, tear-film tolerability, ocular surface integrity, epithelial compatibility, or combinations thereof.
[0149] Example 3: Rabbit Ocular Toxicology Study
[0150] In certain embodiments, the ophthalmic ultraviolet-protective compositions described herein may further demonstrate ocular safety and biocompatibility in a repeated-dose rabbit ocular toxicology evaluation.
[0151] In certain embodiments, rabbits may receive repeated topical ocular administration of a sterile GMP-grade ophthalmic ultraviolet-protective formulation comprising approximately 0.25 wt% ensulizole approximately six times daily for approximately fourteen consecutive days.
[0152] In certain embodiments, repeated administration may demonstrate no observable ocular toxicity, no clinically significant corneal toxicity, no clinically significant conjunctival toxicity, no clinically significant anterior segment toxicity, no clinically significant ocular inflammation, no clinically significant epithelial injury, or any combination thereof.
[0153] In certain embodiments, histopathologic evaluation following repeated administration may demonstrate preservation of normal ocular tissue architecture.
[0154] In certain embodiments, histopathologic evaluation may demonstrate intact corneal epithelium, absence of clinically significant inflammatory infiltrates, absence of clinically significant stromal injury, absence of clinically significant conjunctival injury, absence of clinically significant corneal degeneration, absence of clinically significant epithelial degeneration, absence of clinically significant toxicologic findings, or any combination thereof.
[0155] In certain embodiments, the repeated-dose ocular tolerability findings described herein may demonstrate unexpected ophthalmic biocompatibility of ultraviolet-attenuating ophthalmic formulations comprising ensulizole.
[0156] In certain embodiments, the demonstrated combination of ultraviolet attenuation, ophthalmic tolerability, repeated-dose safety, reduced ocular irritation, preservation of ocular surface integrity, and absence of observable ocular toxicity may distinguish the disclosed compositions from one or more alternative ultraviolet-filtering compounds or formulations.
[0157] In certain embodiments, the compositions described herein may be suitable for repeated daily ophthalmic administration, prophylactic ophthalmic administration, chronic ophthalmic administration, cosmetic ophthalmic administration, environmental ophthalmic exposure protection, or any combination thereof.Attorney Docket No.56964-703601
[0158] Example 4: Exemplary In Vivo UVB Photoprotection Study
[0159] In certain embodiments, the compositions described herein provide in vivo protection against ultraviolet-induced ocular injury.
[0160] In certain embodiments, ultraviolet photoprotection is demonstrated in an in vivo animal model following ultraviolet radiation exposure.
[0161] In certain embodiments, a split-eye rabbit model is utilized to evaluate ultraviolet-protective efficacy of ophthalmic formulations described herein.
[0162] In certain embodiments, one eye of a rabbit is pre-treated with an ophthalmic ultraviolet-protective composition comprising ensulizole prior to controlled ultraviolet radiation exposure, while the contralateral eye is treated with a control ophthalmic formulation prior to exposure to substantially the same ultraviolet radiation conditions.
[0163] In certain embodiments, the control ophthalmic formulation comprises a commercially available lubricating eye drop formulation including Refresh Relieva® or components thereof.
[0164] In certain embodiments, the ultraviolet radiation comprises ultraviolet B (UVB) radiation administered at levels previously demonstrated to induce photoconjunctivitis, conjunctival hyperemia, ocular irritation, corneal edema, epithelial injury, or combinations thereof.
[0165] In certain embodiments, the eye pre-treated with the ultraviolet-protective composition comprising ensulizole demonstrates reduced conjunctival hyperemia, reduced ocular redness, reduced ocular irritation, reduced photoconjunctivitis, reduced corneal edema, reduced epithelial injury, improved ocular surface appearance, improved corneal clarity, or combinations thereof relative to the contralateral control eye following ultraviolet exposure.
[0166] In certain embodiments, the ultraviolet-protective composition demonstrates reduced ultraviolet-induced ocular injury relative to a commercially available ophthalmic lubricant formulation.
[0167] In certain embodiments, the ultraviolet-protective composition demonstrates unexpected in vivo ocular photoprotective activity following ultraviolet exposure.
[0168] FIG. 1 illustrates a schematic of ophthalmic ultraviolet protection provided by ensulizole-containing eye drops. FIG 2A. illustrates a line graph demonstrating the UV absorbance spectrum of eyedrops formulated with 0.25 wt% ensulizole versus commercially available Refresh Optive® Advanced Lubricant Eye Drops. FIG 2B. illustrates a line graph demonstrating the UV absorbance spectrum of eyedrops formulated with 0.25 wt% ensulizole versus commercially available Drop Defence® Anti UV Eyedrops. FIG 2C. illustrates a line graph demonstrating the UV absorbance spectrum of eyedrops formulated with 0.25 wt% ensulizole versus commercially available Rohto® Dual Light Relief Eyedrops.Attorney Docket No.56964-703601
[0169] Example 5: Development Of Ophthalmic Ultraviolet-Protective Formulations
[0170] In certain embodiments, extensive formulation development efforts may be performed to identify ultraviolet-attenuating compounds suitable for topical ophthalmic administration.
[0171] In certain embodiments, greater than twenty distinct ophthalmic ultraviolet-protective formulations may be evaluated.
[0172] In certain embodiments, formulations comprising avobenzone, homosalate, bisethylhexyloxyphenol methoxyphenyl triazine (Tinosorb®), octyl methoxycinnamate, octinoxate, mineral oil, light mineral oil, emulsified oil systems, or any combination thereof may be evaluated.
[0173] In certain embodiments, formulations comprising one or more oil-soluble ultravioletfiltering compounds demonstrated increased ocular irritation, increased stinging, increased visual blurring, reduced optical clarity, poor ophthalmic tolerability, or any combination thereof.
[0174] In certain embodiments, micro-volume ophthalmic delivery systems may be configured to administer approximately 10 pL or less of formulation were evaluated.
[0175] In certain embodiments, substantial ocular blurring, stinging, irritation, or any combination thereof may persist despite reduced administration volumes.
[0176] In certain embodiments, phenylbenzimidazole sulfonic acid (ensulizole; PBSA) may demonstrate unexpectedly improved suitability for ophthalmic ultraviolet-protective formulations relative to one or more alternative ultraviolet-filtering compounds.
[0177] In certain embodiments, ensulizole may demonstrate improved optical clarity, reduced visual blurring, reduced ocular irritation, improved aqueous compatibility, improved ophthalmic tolerability, improved formulation stability, improved sterilization compatibility, or any combination thereof relative to one or more oil-soluble ultraviolet-filtering compounds.
[0178] In certain embodiments, ensulizole may demonstrate compatibility with sterile ophthalmic filtration processes, radiation sterilization processes, preservative-free ophthalmic systems, aqueous ophthalmic vehicles, or any combination thereof.
[0179] In certain embodiments, ensulizole may contribute to osmolarity-modifying properties of the ophthalmic formulation.
[0180] In certain embodiments, osmolarity-modifying properties may contribute to improved ocular comfort, improved tear-film stability, improved ocular surface hydration, improved environmental tolerability, improved dry-climate tolerability, improved sunny-climate tolerability, or any combination thereof.
[0181] In certain embodiments, the combination of ultraviolet attenuation, aqueous compatibility, reduced blurring, reduced irritation, sterilization compatibility, formulation stability, osmoprotective compatibility, ophthalmic comfort, prolonged ocular surface retention,Attorney Docket No. 56964-703601and ocular photoprotective activity may unexpectedly render ensulizole particularly suitable for topical ophthalmic ultraviolet-protective formulations.
[0182] Although specific embodiments are described herein, one of ordinary skill in the art will recognize that numerous modifications, substitutions, and variations are possible without departing from the scope of the present disclosure.
[0183] ADDITIONAL EMBODIMENTS
[0184] Embodiment 1: A formulation comprising: about 0.25 wt% to about 15 wt% of ensulizole and a second therapeutic agent.
[0185] Embodiment 2: The formulation of Embodiment 1, wherein the second therapeutic agent is selected from glycerin, propylene glycol, Soothe® Dry Eye, Biotrue® Hydration Boost Lubricant Eye Drops, Biotrue® Hydration Boost Lubricant Eye Drops, Blink® Triple Care Lubricating Eye Drops, Blink GelTears® Lubricating Eye Drops, Soothe® XP Emollient Eye Drops, Advanced Eye Relief / Redness Instant Relief, Alaway® Antihistamine Eye Drops, Opcon-A® Allergy Relief Eye Drops, Acuvail®, Pred Forte®, Lastacaft®, Combigan®, Lumigan®, Alphagan®, Refresh® Digital, Refresh® Relieva® PF Xtra, RefreshMega 3®, Refresh Optive ®, Resistasis®, Vuity®, Acular®, Albalon®, Albalon A®, FML Liquifilm® eyedrops, Celluvisc®, and Ganafort®.
[0186] Embodiment 3: An ophthalmic composition comprising about 0.25 wt% to about 15 wt% of ensulizole and a second therapeutic agent.
[0187] Embodiment 4: The ophthalmic composition of Embodiment 3, wherein the second therapeutic agent is selected from glycerin, propylene glycol, Soothe® Dry Eye, Biotrue® Hydration Boost Lubricant Eye Drops, Biotrue® Hydration Boost Lubricant Eye Drops, Blink® Triple Care Lubricating Eye Drops, Blink GelTears® Lubricating Eye Drops, Soothe® XP Emollient Eye Drops, Advanced Eye Relief / Redness Instant Relief, Alaway® Antihistamine Eye Drops, Opcon-A® Allergy Relief Eye Drops, Acuvail®, Pred Forte®, Lastacaft®, Combigan®, Lumigan®, Alphagan®, Refresh® Digital, Refresh® Relieva® PF Xtra, RefreshMega 3®, Refresh Optive ®, Resistasis®, Vuity®, Acular®, Albalon®, Albalon A®, FML Liquifilm® eyedrops, Celluvisc®, and Ganafort®.
[0188] Embodiment 5: An ophthalmic sunscreen composition comprising about 0.25 wt% to about 15 wt% of ensulizole and a second therapeutic agent.
[0189] Embodiment 6: The ophthalmic sunscreen composition of Embodiment 5, wherein the second therapeutic agent is selected from glycerin, propylene glycol, Soothe® Dry Eye, Biotrue® Hydration Boost Lubricant Eye Drops, Biotrue® Hydration Boost Lubricant Eye Drops, Blink® Triple Care Lubricating Eye Drops, Blink GelTears® Lubricating Eye Drops, Soothe® XP Emollient Eye Drops, Advanced Eye Relief / Redness Instant Relief, Alaway®Attorney Docket No.56964-703601Antihistamine Eye Drops, Opcon-A® Allergy Relief Eye Drops, Acuvail®, Pred Forte®, Lastacaft®, Combigan®, Lumigan®, Alphagan®, Refresh® Digital, Refresh® Relieva® PF Xtra, RefreshMega 3®, Refresh Optive ®, Resistasis®, Vuity®, Acular®, Albalon®, Albalon A®, FML Liquifilm® eyedrops, Celluvisc®, and Ganafort®.
[0190] Embodiment 7: A method of ocular UV protection, the method comprising applying an ophthalmic composition to an eye, wherein the ophthalmic composition comprises about 0.25 wt% to about 15 wt% of ensulizole and a second therapeutic agent.
[0191] Embodiment 8: The method of Embodiment 7, wherein the second therapeutic agent is selected from glycerin, propylene glycol, Soothe® Dry Eye, Biotrue® Hydration Boost Lubricant Eye Drops, Biotrue® Hydration Boost Lubricant Eye Drops, Blink® Triple Care Lubricating Eye Drops, Blink GelTears® Lubricating Eye Drops, Soothe® XP Emollient Eye Drops, Advanced Eye Relief / Redness Instant Relief, Alaway® Antihistamine Eye Drops, Opcon-A® Allergy Relief Eye Drops, Acuvail®, Pred Forte®, Lastacaft®, Combigan®, Lumigan®, Alphagan®, Refresh® Digital, Refresh® Relieva® PF Xtra, RefreshMega 3®, Refresh Optive ®, Resistasis®, Vuity®, Acular®, Albalon®, Albalon A®, FML Liquifilm® eyedrops, Celluvisc®, and Ganafort®.
Claims
Attorney Docket No.56964-703601CLAIMS WHAT IS CLAIMED IS:
1. A formulation comprising:about 0.25 wt% to about 15 wt% of ensulizole; anda second therapeutic agent.
2. The formulation of claim 1, wherein the second therapeutic agent is selected from glycerin, propylene glycol, Soothe® Dry Eye, Biotrue® Hydration Boost Lubricant Eye Drops, Blink® Triple Care Lubricating Eye Drops, Blink GelTears® Lubricating Eye Drops, Soothe® XP Emollient Eye Drops, Advanced Eye Relief / Redness Instant Relief, Alaway® Antihistamine Eye Drops, Opcon-A® Allergy Relief Eye Drops, Acuvail®, Pred Forte®, Lastacaft®, Combigan®, Lumigan®, Alphagan®, Refresh® Digital, Refresh® Relieva® PF Xtra, RefreshMega 3®, Refresh Optive ®, Resistasis®, Vuity®, Acular®, Albalon®, Albalon A®, FML Liquifilm® eyedrops, Celluvisc®, and Ganafort®.
3. The formulation of claim 1 or claim 2, wherein the second therapeutic agent is In some embodiments, the second therapeutic agent is selected from povidone, glycerin, polyethylene glycol 300, polyethylene glycol 400, carboxymethylcellulose, Polysorbate 80, light mineral oil, mineral oil, naphazoline hydrochloride, ketotifen, pheniramine maleate, ketorolac tromethamine, prednisolone acetate, alcaftadine, brimonidine tartrate, timolol maleate, bimatoprost, Brimonidine tartrate, Cyclosporine, Pilocarpine hydrochloride, ketorolac trometamol, antazoline phosphate, fluoromethoIone, and carmellose sodium, or any combination thereof.
4. The formulation of any one of claims 1-3, wherein the formulation comprises about 0.25 wt% of ensulizole.
5. An ophthalmic composition comprising:about 0.25 wt% to about 15 wt% of ensulizole; anda second therapeutic agent.
6. The ophthalmic composition of claim 5, wherein the second therapeutic agent is selected from glycerin, propylene glycol, Soothe® Dry Eye, Biotrue® Hydration Boost Lubricant Eye Drops, Blink® Triple Care Lubricating Eye Drops, Blink GelTears® Lubricating Eye Drops, Soothe® XP Emollient Eye Drops, Advanced Eye Relief / Redness Instant Relief, Alaway® Antihistamine Eye Drops, Opcon-A® Allergy Relief Eye Drops, Acuvail®, Pred Forte®, Lastacaft®, Combigan®, Lumigan®, Alphagan®, Refresh® Digital, Refresh® Relieva® PFAttorney Docket No.56964-703601Xtra, RefreshMega 3®, Refresh Optive ®, Resistasis®, Vuity®, Acular®, Albalon®, Albalon A®, FML Liquifilm® eyedrops, Celluvisc®, and Ganafort®.
7. The ophthalmic composition of claim 5 or claim 6, wherein the second therapeutic agent is In some embodiments, the second therapeutic agent is selected from povidone, glycerin, polyethylene glycol 300, polyethylene glycol 400, carboxymethylcellulose, Polysorbate 80, light mineral oil, mineral oil, naphazoline hydrochloride, ketotifen, pheniramine maleate, ketorolac tromethamine, prednisolone acetate, alcaftadine, brimonidine tartrate, timolol maleate, bimatoprost, Brimonidine tartrate, Cyclosporine, Pilocarpine hydrochloride, ketorolac trometamol, antazoline phosphate, fluorometholone, and carmellose sodium, or any combination thereof.
8. The ophthalmic composition of any one of claims 5-7, wherein the ophthalmic composition comprises about 0.25 wt% of ensulizole.
9. An ophthalmic sunscreen composition comprising:about 0.25 wt% to about 15 wt% of ensulizole; anda second therapeutic agent.
10. The ophthalmic sunscreen composition of claim 9, wherein the second therapeutic agent is selected from glycerin, propylene glycol, Soothe® Dry Eye, Biotrue® Hydration Boost Lubricant Eye Drops, Blink® Triple Care Lubricating Eye Drops, Blink GelTears® Lubricating Eye Drops, Soothe® XP Emollient Eye Drops, Advanced Eye Relief / Redness Instant Relief, Alaway® Antihistamine Eye Drops, Opcon-A® Allergy Relief Eye Drops, Acuvail®, Pred Forte®, Lastacaft®, Combigan®, Lumigan®, Alphagan®, Refresh® Digital, Refresh® Relieva® PF Xtra, RefreshMega 3®, Refresh Optive ®, Resistasis®, Vuity®, Acular®, Albalon®, Albalon A®, FML Liquifilm® eyedrops, Celluvisc®, and Ganafort®.
11. The ophthalmic sunscreen composition of claim 9 or claim 10, wherein the second therapeutic agent is In some embodiments, the second therapeutic agent is selected from povidone, glycerin, polyethylene glycol 300, polyethylene glycol 400, carboxymethylcellulose, Polysorbate 80, light mineral oil, mineral oil, naphazoline hydrochloride, ketotifen, pheniramine maleate, ketorolac tromethamine, prednisolone acetate, alcaftadine, brimonidine tartrate, timolol maleate, bimatoprost, Brimonidine tartrate, Cyclosporine, Pilocarpine hydrochloride, ketorolac trometamol, antazoline phosphate, fluorometholone, and carmellose sodium, or any combination thereof.Attorney Docket No.56964-70360112. The ophthalmic sunscreen composition of any one of claims 9-11, wherein the ophthalmic sunscreen composition comprises about 0.25 wt% of ensulizole.
13. A method of ocular UV protection, the method comprising applying an ophthalmic composition to an eye, wherein the ophthalmic composition comprises:about 0.25 wt% to about 15 wt% of ensulizole; anda second therapeutic agent.
14. The method of claim 13, wherein the second therapeutic agent is selected from glycerin, propylene glycol, Soothe® Dry Eye, Biotrue® Hydration Boost Lubricant Eye Drops, Blink® Triple Care Lubricating Eye Drops, Blink GelTears® Lubricating Eye Drops, Soothe® XP Emollient Eye Drops, Advanced Eye Relief / Redness Instant Relief, Alaway® Antihistamine Eye Drops, Opcon-A® Allergy Relief Eye Drops, Acuvail®, Pred Forte®, Lastacaft®, Combigan®, Lumigan®, Alphagan®, Refresh® Digital, Refresh® Relieva® PF Xtra, RefreshMega 3®, Refresh Optive ®, Resistasis®, Vuity®, Acular®, Albalon®, Albalon A®, FML Liquifilm® eyedrops, Celluvisc®, and Ganafort®.
15. The method of claim 13 or claim 14, wherein the second therapeutic agent is In some embodiments, the second therapeutic agent is selected from povidone, glycerin, polyethylene glycol 300, polyethylene glycol 400, carboxymethylcellulose, Polysorbate 80, light mineral oil, mineral oil, naphazoline hydrochloride, ketotifen, pheniramine maleate, ketorolac tromethamine, prednisolone acetate, alcaftadine, brimonidine tartrate, timolol maleate, bimatoprost, Brimonidine tartrate, Cyclosporine, Pilocarpine hydrochloride, ketorolac trometamol, antazoline phosphate, fluoromethoIone, and carmellose sodium, or any combination thereof.
16. The method of any one of claims 13-15, wherein ophthalmic composition comprises about 0.25 wt% ensulizole.
